BMJ Ischaemic Stroke

Ischaemic stroke
The right clinical information, right where it's needed
Last updated: Dec 06, 2018

Table of Contents
Summary 3
Basics 4
Definition 4
Epidemiology 4
Aetiology 4
Pathophysiology 5
Classification 5
Prevention 7
Primary prevention 7
Secondary prevention 7
Diagnosis 9
Case history 9
Step-by-step diagnostic approach 9
Risk factors 13
History & examination factors 16
Diagnostic tests 20
Differential diagnosis 24
Treatment 26
Step-by-step treatment approach 26
Treatment details overview 30
Treatment options 32
Follow up 42
Recommendations 42
Complications 43
Prognosis 44
Guidelines 45
Diagnostic guidelines 45
Treatment guidelines 46
Online resources 49
Evidence scores 50
References 51
Images 61
Disclaimer 65
Summary
◊ A leading cause of morbidity and mortality.
◊ Approximately 85% of strokes are ischaemic, caused by vascular occlusion.
◊ A clinical emergency: timely diagnosis, triage, and intervention can improve outcome.
◊ Care of patients in dedicated stroke units improves survival and function.
◊ Intravenous recombinant tissue plasminogen activator is given within 4.5 hours of stroke onset.
◊ Endovascular interventions, such as clot retrieval devices or intra-arterial thrombolysis, can be used
in carefully selected patients within 6 hours of ischaemic stroke onset.
Ischaemic stroke Basics
Definition
Stroke is defined as an acute neurological deficit lasting more than 24 hours and caused by cerebrovascular
aetiology. It is further subdivided into ischaemic stroke (caused by vascular occlusion or stenosis) and
BASICS
haemorrhagic stroke (caused by vascular rupture, resulting in intraparenchymal and/or subarachnoid

haemorrhage). Central venous sinus thrombosis is a rare form of stroke that occurs due to thrombosis of the
dural venous sinuses. This monograph deals with ischaemic stroke.
Transient ischaemic attack (TIA) is defined as a transient episode of neurological dysfunction caused by focal
brain, spinal cord, or retinal ischaemia, without acute infarction. Patients with TIAs are at high risk for early
ischaemic stroke,[1] and their risk may be stratified by clinical scale, vessel imaging, and diffusion magnetic
resonance imaging.[2] This replaced the former definition of focal neurological impairment lasting less than
24 hours.
Epidemiology
Stroke is the third leading cause of death and a major cause of disability in the US[6] and in England and
Wales, and the third leading cause of death in Canada.[7] In Scotland in 2016/17 the incident rate for
stroke, standardised by age-sex, was 180 per 100,000.[8] There are approximately 610,000 new strokes
per year in the US.[9] Ischaemic stroke accounts for 87% of all stroke cases, haemorrhagic stroke for
10%, and subarachnoid haemorrhage for 3%.[9] Ischaemic stroke prevalence can be further sub-divided
according to pathophysiological mechanism: extracranial atherosclerosis (10%), intracranial atherosclerosis
(10%), cardioembolic (25%), lacunar infarction ([small vessel disease] 15%), indeterminate aetiology ([i.e.,
cryptogenic] 30%), or other defined causes (10%). Ischaemic stroke is more common in older people, people
with lower levels of education, and African-American or Hispanic people.[9] The overall incidence of stroke as
well as stroke mortality has been decreasing over the last few decades, presumably due to effective primary
prevention and management.
Aetiology
Ischaemic stroke is a syndrome, not a disease. It is caused by a transient or permanent critical reduction
in cerebral blood flow due to arterial occlusion or stenosis. Identification of the underlying mechanisms and
aetiologies is important so that appropriate therapy can be initiated to decrease the risk of recurrent stroke.
A classification scheme for ischaemic stroke developed for the Trial of Org 10172 in Acute Stroke Treatment
(TOAST) provides a framework for determining the stroke mechanism, with implications for identifying the
underlying aetiology:[3]
Large artery atherosclerosis affects the extracranial carotid or vertebral arteries, or less commonly the major
intracranial arteries. It is a site for thrombus formation that then embolises to distal sites and/or occludes the
vessel.
Small vessel (lacunar) stroke is caused by thrombotic occlusion of a small penetrating artery affected by
lipohyalinosis (lipid accumulation due to ageing and hypertension), resulting in a <1.5-cm infarct in the
perfusion territory of the affected small vessel.
4 This PDF of the BMJ Best Practice topic is based on the web version that was last updated: Dec 06, 2018.
BMJ Best Practice topics are regularly updated and the most recent version
of the topics can be found on bestpractice.bmj.com . Use of this content is
subject to our disclaimer. © BMJ Publishing Group Ltd 2020. All rights reserved.
Cardioembolism results from thrombus formation in the heart, which then embolises to the intracranial
circulation, and is associated with cardiac disease such as atrial fibrillation. Accumulating evidence suggests
that aortic atherosclerotic plaque is another potential source of thrombus formation with embolism.
BASICS
Strokes of other determined aetiology may be caused by various diseases of the intracranial or extracranial
vessels (e.g., dissection, vasculitis, venous thrombosis) or haematological system (e.g., sickle cell anaemia,
antiphospholipid antibody syndrome, and other hypercoagulable states).
Strokes of indeterminate aetiology, despite complete work-up, are not uncommon. In the Northern Manhattan
Stroke Study, 32% of strokes had no identifiable aetiology.[10]
Pathophysiology
Regardless of the aetiology, ischaemic stroke occurs when blood supply in a cerebral vascular territory is
critically reduced due to occlusion or critical stenosis of a cerebral artery. A minority of ischaemic strokes are
caused by cerebral sinus or cortical vein thrombosis. These are frequently associated with a prothrombotic
(hypercoagulable or hyperaggregable) state, with resulting venous insufficiency and reduced blood flow.
Pathophysiologically, ischaemic stroke can be broadly classified as:
• Primary vascular pathologies (e.g., atherosclerosis, aortic arch atherosclerosis, arterial dissection,
migraine, or vasculitis) that directly reduce cerebral perfusion and/or result in artery-to-artery embolism
(i.e., stenosis or occlusion of a distal artery by an embolus originating in a proximal artery)
• Cardiac pathologies (e.g., atrial fibrillation, myocardial ischaemia/infarction, patent foramen ovale) that
lead to cerebral arterial occlusion due to embolism
• Haematological pathologies (e.g., prothrombotic hypercoagulable or hyperaggregable states) that

directly precipitate cerebrovascular thrombosis (particularly venous), or facilitate systemic venous or
intracardiac thrombus formation and cardioembolism.
Classification
Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria[3]
Classifies ischaemic stroke according to pathophysiology:
Large artery atherosclerosis
• Infarction in the perfusion territory of an extracranial or intracranial artery with >50% stenosis, and no
other likely cause of stroke.
Cardioembolism
• Infarction in the presence of at least 1 cardiac condition strongly associated with stroke, such as atrial
fibrillation.
Small vessel occlusion
• Infarction <1.5 cm in diameter in the perfusion territory of a small penetrating blood vessel.
This PDF of the BMJ Best Practice topic is based on the web version that was last updated: Dec 06, 2018.
5
Stroke of other determined aetiology
• Examples include cerebral infarction caused by vasculitis, arterial dissection, and hypercoagulable
states.
BASICS
Stroke of indeterminate aetiology
• Infarction in the setting of 2 or more different potential aetiologies, no potential aetiology despite
complete diagnostic evaluation, or an incomplete evaluation.
Causative classification of stroke modified TOAST criteria[4]

This web-based validated classification algorithm sub-types ischaemic stroke according to pathophysiological
mechanism. Categories are:
• Large artery atherosclerosis

• Cardio-aortic embolism
• Small artery occlusion
• Other causes
• Indeterminate causes.
Indeterminate causes are divided into:
• Unknown - embolic stroke of undetermined source

• Unknown - multiple causes
• Unknown - incomplete evaluation.
Each sub-type except for the indeterminate group is sub-divided based on the weight of evidence as:
• Evident
• Probable
• Possible.
Oxford Community Stroke Project classification system[5]

Sub-types ischaemic stroke according to vascular territory of infarction:
• Total anterior circulation infarction

• Partial anterior circulation syndrome
• Lacunar infarction
• Posterior circulation infarction.
Ischaemic stroke Prevention
Primary prevention
Established measures for primary prevention of stroke include physical activity; avoidance of obesity; good
nutrition; treatment of hypertension,[41] [42] hypercholesterolaemia, and diabetes; and abstinence from
smoking, illegal drug use, or heavy drinking.[43] Further preventative measures may be appropriate in
particular patient groups.
Unstable carotid atherosclerotic plaque leading to stroke is a major cause of morbidity and mortality.
Based on a Cochrane review, adjusted-dose warfarin and related oral anticoagulants reduce stroke, disabling
stroke, and other major vascular events for those with non-valvular atrial fibrillation by about one third when
compared with antiplatelet therapy.[44] Nonetheless, the benefits of anticoagulation therapy should be
weighed against the risk of haemorrhage, particularly intracranial haemorrhage, for each patient.
In patients with non-valvular atrial fibrillation, dabigatran, rivaroxaban, apixaban, and edoxaban are as
effective as warfarin in preventing stroke and carry a smaller risk of intracranial bleeding. The combination of
triflusal plus acenocoumarol is likely to be more effective than acenocoumarol alone in reducing stroke risk;
however, these drugs are not widely used and availability may vary.[45]
The human monoclonal antibody evolocumab has been approved by the Food and Drug Administration in
PREVENTION
the US for the prevention of stroke, heart attack, and coronary revascularisations in adults with established
cardiovascular disease. Evolocumab works by inhibiting proprotein convertase subtilisin/kexin type 9 from
binding to low-density lipoprotein (LDL) receptors, increasing the number of LDL receptors available to clear
LDL from the blood, thereby lowering LDL-cholesterol levels.
Because transient ischaemic attack (TIA) is a form of stroke, prevention of further stroke in a patient with TIA
places it under the category of secondary stroke prevention.
Secondary prevention
Recommendations for the secondary prevention of ischaemic stroke have been published.[61] Established
trial-confirmed therapies for secondary ischaemic stroke prevention include:
• Anticoagulation with warfarin for atrial fibrillation.[116] Range INR should be 2.0 to 3.0 for patients
treated with a vitamin-K antagonist.[117] The HAS-BLED score may be used to assess the bleeding
risk of the patient; if high, the patient should be followed up more closely.[118] The SAME-TTR score
may be used to decide whether the patient should be treated with a non-vitamin-K oral anticoagulant
or a vitamin-K antagonist.[119]
• Antiplatelet drug therapy for non-atrial fibrillation patients.[120] [121] Based on a systematic review of
studies addressing the role of clopidogrel and modified-release dipyridamole (MRD) for the prevention
of occlusive vascular events, the evidence suggests that the most cost-effective treatment for patients
with ischaemic stroke/transient ischaemic attack (TIA) is clopidogrel followed by MRD plus aspirin,
followed by aspirin; for patients with myocardial infarction, aspirin followed by clopidogrel; and for
patients with established peripheral arterial disease or multi-vascular disease, clopidogrel followed
by aspirin.[122] Cilostazol is a new emerging potential and feasible option in acute ischaemic stroke,
and comparable to aspirin in its efficacy and safety.[123] A cohort study has found that older people
receiving daily aspirin-based antiplatelet treatment without routine proton-pump inhibitor (PPI) use
are at higher and more sustained risk of major bleeding than younger patients. In this study, half of
the major bleedings in patients aged 75 or older were upper gastrointestinal. The estimated numbers
needed to treat for routine PPI use to prevent major upper gastrointestinal bleed were low and the
authors concluded that co-prescription should be encouraged.[124]
• Carotid endarterectomy for carotid artery stenosis.[19] [20] In patients with a recent symptomatic
carotid stenosis (i.e., TIA or non-disabling stroke), endarterectomy is of some benefit for 50% to 69%
of symptomatic stenosis and highly beneficial for 70% to 99% of stenosis without near-occlusion. No
evidence of benefit was found in patients with near-occlusion.[125] Based on a large meta-analysis,
carotid artery stenting is associated with an elevated risk of both peri-procedural and intermediate- to
7
Ischaemic stroke Prevention
long-term harmful outcomes, but with a reduction in peri-procedural myocardial infarction and cranial
nerve injury, compared with carotid artery endarterectomy for people with carotid artery disease.
Strategies are urgently needed to identify patients who are best served by carotid artery stenting
compared with carotid endarterectomy.[126]
• Statin therapy with intensive lipid-lowering effects is recommended for patients with ischaemic stroke
or TIA, to lower the risk of stroke and cardiovascular events.[61] Ezetimibe may be added to decrease
LDL-cholesterol levels further.[127] Patients who are at a very high risk for stroke recurrence and have
high LDL-cholesterol levels despite intensive lipid-lowering treatment may benefit from a proprotein
convertase subtilisin/kexin type 9 inhibitor.
• Additional secondary prevention measures may be necessary depending on stroke risk factors and
associated diseases discovered during investigations for the cause of stroke.[61]
• In stroke patients or those with TIA and obesity, the treating physician should consider sleep studies
because sleep apnoea is common among this subgroup of patients and treatment of apnoea with
continuous positive airway pressure may improve outcomes.[61]
• In patients with embolic stroke of undetermined source and a patent foramen ovale (PFO) who have a
high ROPE score, closure of the PFO may be of benefit for secondary stroke prevention.[127]
PREVENTION
Ischaemic stroke Diagnosis
Case history
Case history #1
A 70-year-old right-handed man is discovered by a family member to have difficulty speaking and
comprehending spoken language, and an inability to raise his right arm. He was last known to be fully
functional 1 hour ago when the family member spoke to him by phone. There is a history of treated
hypertension and diabetes.
Other presentations
The presenting symptoms of stroke vary by cerebral location. Most common symptoms are partial or
total loss of strength in upper and/or lower extremities, expressive and/or receptive language dysfunction,
sensory loss in upper and/or lower extremities, visual field loss, slurred speech, or difficulty with fine
motor co-ordination and gait. In most cases the symptoms appear rapidly, over seconds or minutes,
and may be preceded by one or more transient ischaemic attacks. There are no symptoms or signs
that reliably distinguish between ischaemic and haemorrhagic stroke. The acute onset of neurological
symptoms referable to the brain territory of a cerebral artery strongly suggests ischaemic stroke, but
mimicking conditions such as intracerebral haemorrhage, focal seizure, and complicated migraine need to
be considered and excluded.
Step-by-step diagnostic approach

The goals of the initial evaluation are to identify the stroke syndrome, ensure medical stability, perform an
abbreviated neurological examination (e.g., National Institutes of Health [NIH] Stroke Scale),
[VIDEO: NIH Stroke Score ]
DIAGNOSIS
and rapidly transport the patient to the computed tomography (CT) or magnetic resonance imaging (MRI)
scanner to begin scanning as soon as possible.[46] Because of time constraints, certain portions of
the history and physical examination may be deferred until after scanning and the decision to perform
thrombolysis. This is because the sensitivity and specificity to correctly diagnose and localise ischaemic
stroke from the neurological history and examination are fairly low. Additionally, many other neurological
conditions can mimic stroke. The proper diagnosis of stroke requires craniocervical CT or MRI.
In many cases, consultation with a stroke physician is helpful. This is particularly true when thrombolysis or
other acute reperfusion therapies are contemplated; guidelines recommend that thrombolysis be given by
stroke physicians following institutional written care protocols.[46]
Time of onset
The most important information in the history, apart from the presence of neurological symptoms, is
the time of onset. Time from stroke onset is the main factor that determines eligibility for acute stroke
treatments. The time of onset is not always easy to determine, particularly if the onset was not witnessed
and the patient is unable to communicate; symptoms are mild and not immediately noticeable; or there
is a stuttering or fluctuating course. In the frequent situation where the onset was unwitnessed, the
appropriate operational definition of symptom onset is the time when patient was last known to be
9
unaffected. This also implies that if signs and symptoms completely resolve during a fluctuating course,
the clock for determining eligibility for recanalisation may be reset.
Prior medical information relevant to the acute management of stroke includes:
• Recent stroke
• Seizure or epilepsy
• Myocardial infarction
• Atrial fibrillation
• Recent surgery
• Recent trauma
• Bleeding
• History of haemorrhagic stroke
• Comorbidities (specifically hypertension and diabetes)
• Current or past illicit drug use
• Medicines (specifically anticoagulants, insulin, and antihypertensives).
Other risk factors include older age, male gender, African-American or Hispanic ancestry, smoking, other
comorbid cardiac conditions, carotid artery stenosis, and sickle cell disease.
Physicians as well as the emergency medical team attending to the patient in the field should establish
contact with witnesses or next of kin (or person with a legal right to make healthcare decisions on behalf
of the patient, such as a healthcare proxy). This is necessary not only to obtain an accurate and relevant
history but also to seek consent for invasive tests or treatments if needed.
Presenting symptoms
The presenting symptoms of stroke are highly variable depending on the mechanism and location of
stroke.
The most common anterior circulation stroke symptoms are:

DIAGNOSIS
• Limb and/or facial weakness

• Paraesthesias or numbness
• Speech difficulty
• Headache.
Posterior circulation strokes often present with:
• Visual loss or double vision

• Confusion
• Dizziness
• Vertigo
• Nausea.
Arterial dissections may present with:
• Neck or facial pain.

Lacunar strokes often present with:
• Limb and/or facial weakness (typically affects face, leg, and arm equally)
• Speech difficulty
• Ataxia
• Paraesthesias or numbness (typically affects face, leg, and arm equally).
In most cases, the symptoms of ischaemic stroke appear rapidly, over seconds or minutes. One or more
transient ischaemic attacks (TIAs), which may be stereotypical, sometimes precede the stroke as warning
signs or symptoms. Their prompt identification with proper intervention is essential in stroke prevention.
Because stroke can be the result of a general medical illness, such as a hypercoagulable state perhaps
associated with a malignancy, or cardiac ischaemia or arrhythmia, a thorough history is often very helpful
to tailor specific management.
The ABCD2 score is a risk assessment tool that can help predict short-term stroke risk following TIA.[47]
[VIDEO: ABCD2 Score to Predict Stroke Risk after TIA ]

The score is optimised to predict the risk of stroke within 2 days after a TIA, but can also predict stroke
risk within 90 days.
Physical examination and neurological assessment

Initial assessment
• Should aim to identify airway, breathing, and circulatory insufficiencies requiring urgent treatment.
General systemic examination should seek evidence of risk factors, such as cardiac arrhythmias
or valvular pathology. Arrhythmias, murmurs, and pulmonary oedema are associated with cardiac
comorbidities, which predispose patients to stroke disease.
Neurological assessment
• As with the symptomatology, presenting signs of stroke can be highly variable depending on its
mechanism and location.
Anterior circulation strokes are commonly associated with:
DIAGNOSIS
• Partial or total loss of strength in face and upper and/or lower extremities (usually unilateral)
• Expressive and/or receptive language dysfunction (aphasia)
• Sensory loss in face and upper and/or lower extremities (associated with sensory neglect if non-
dominant hemisphere stroke)
• Gaze paresis (often horizontal and unidirectional). Wrong-way eye deviation (i.e., gaze deviation
away from the side of the brain lesion, towards the hemiparetic side) should prompt consideration
of seizure but can also occur with strokes affecting the pons or thalamus. Horner's syndrome
suggests ipsilateral carotid dissection.
Posterior circulation strokes are more commonly associated with:
• Specific cranial nerve deficits: for example, unilateral tongue weakness, diplopia
• Horner's syndrome (hemilateral triad of miosis, ptosis, and facial anhidrosis)
• Visual field loss
• Dysarthria
• Nausea and/or vomiting
• Difficulty with fine motor co-ordination and gait
• Possible altered level of consciousness and coma.
11
Lacunar strokes are associated with:
• Pure motor hemiparesis

• Pure sensory hemiparesis
• Ataxia
• Mixed motor and sensory signs
• Dysarthria.
To ensure timely but adequate neurological evaluation in acute stroke, the NIH Stroke Scale is a useful
tool for measurement of stroke-related deficits.
[VIDEO: NIH Stroke Score ]
Initial testing
After initial life support including management of airway, breathing, and circulation, the next immediate
goal is to rapidly obtain a brain image, typically a non-contrast head CT, in order to exclude a brain
haemorrhage. The ideal time from emergency department arrival to start of CT is 25 minutes.[46]
Imaging of the brain and its feeding vessels plays a crucial role in the diagnosis and better treatment of
patients with TIA or ischaemic strokes. All patients with TIA or possible ischaemic stroke should initially
undergo a CT scan of the brain to rule out intracranial haemorrhage. This test is relatively fast and
inexpensive. MRI of the brain, particularly with diffusion-weighted and gradient-echo sequences, provides
more accurate information about the stroke lesion, clearly highlights the area of ischaemic infarct, and
may provide further clues about the cause(s). However, in many medical centres around the world, MRI
is not available. Therefore, it is recommended that all patients with ischaemic stroke undergo a CT scan
of the brain without contrast, and then MRI of the brain if available.[48] Both CT and MRI data should be
reviewed and interpreted by a physician with expertise in stroke imaging.
[Fig-1]
[Fig-2]
DIAGNOSIS
[Fig-3]
While CT/MRI transport is being organised there should be simultaneous placement of an intravenous
catheter with blood sampling for:
• Serum glucose
• FBC
• Electrolytes
• Urea and creatinine
• Partial thromboplastin and prothrombin times (with international normalised ratio)
• Cardiac enzymes
An ECG should be performed to exclude cardiac arrhythmia or ischaemia, which are relatively common
in ischaemic stroke. Present diagnostic protocols suggest a minimum of 24 hours of ECG monitoring
after an ischaemic stroke to exclude atrial fibrillation. However, it has been found that ECG monitoring
along with insertable cardiac monitor was superior to conventional ECG monitoring in diagnosing atrial
fibrillation in cases of cryptogenic stroke.[49] In addition, one significant issue is that in patients with
cryptogenic stroke or TIA who are 55 years old or older, non-invasive ambulatory ECG with a target
of 30 days should be utilised because this enables clinicians to diagnose and treat paroxysmal atrial
fibrillation.[50]
It is important to note that administration of recombinant tissue plasminogen activator (r-tPA) should not
be delayed by these additional tests unless a specific contraindication is suspected and must be ruled
out: for example, the presence of hypoglycaemia has been associated with autonomic and neurological
symptoms, including stroke mimics and seizures, and hyperglycaemia has been associated with
intracerebral bleeding and worse clinical outcomes in patients treated with r-tPA; both hypoglycaemia and
hyperglycaemia can be excluded by bedside glucose test.[51] Blood glucose should be normalised before
initiating r-tPA treatment.[51] The recommended target time for provision of thrombolysis, if indicated, is
as soon as possible, and should be no longer than 60 minutes from emergency department arrival.[46]
Subsequent testing
Includes:
• CT angiography preferably (or MR angiography). Should be performed in all patients with

acute ischaemic stroke with suspicion of a large vessel occlusion who would be candidates for
endovascular thrombectomy.[51]
• Serum toxicology screen. Performed in selected patients if there is a suspicion of ingestion of toxic
substances. Signs and symptoms may mimic stroke.
• In the presence of cardiopulmonary signs or symptoms, a CXR can detect other relevant conditions
such as cardiomegaly, aortic dissection, or pneumonia.
Optional vascular imaging

Ultrasound studies of intracranial vessels (transcranial Doppler) or cervical carotids may be helpful to
complement the MR or CT angiographic data, and can continuously monitor changes in flow velocity.
In ischaemic stroke, conventional angiography is reserved for patients in whom endovascular intervention
is an option, or if more information is needed to better understand the haemodynamic status of ischaemic
brain (e.g., to define collateral blood supply) for further management (e.g., revascularisation).
DIAGNOSIS
If routine imaging studies fail to show arterial occlusion, and if the infarct imaging and clinical presentation
show characteristics of venous stroke (e.g., ischaemic tissue not conforming to a vascular territory,
severe haemorrhagic transformation and/or oedema, intractable seizures at presentation, signs of
increased intracranial pressure), then patency of cerebral venous sinuses can be assessed by CT or MR
venography.
Emerging tests
CT- or MRI-perfusion-weighted imaging identifies cerebral regions with reduced blood flow that may be
at risk for subsequent infarction. This has been proposed as a means of selecting patients, presenting
beyond 4.5 hours, who have hypoperfused but still viable tissue. These imaging methods are promising
but have not yet been fully validated for patient selection for reperfusion therapies.[52]
[Fig-4]
Risk factors
13
Strong
older age
• Even after controlling for other age-related conditions such as hypertension, this remains a strong non-
modifiable risk factor.[9]
family history of stroke

• Stroke-causing genetic disorders with mendelian inheritance are rare. However, twin studies show that
a significant portion of stroke risk is heritable, and epidemiological studies show that family history of
stroke is a risk factor.[11]
• Numerous candidate genes have been proposed, but none have yet been consistently replicated as a
strong risk factor for stroke.[12]
history of ischaemic stroke

• History of previous ischaemic stroke indicates that the patient may sustain more ischaemic strokes in
the future (particularly if risk factors, e.g., hypertension, are not corrected).
hypertension
• Strongly associated with increased incidence of ischaemic stroke.[13]
smoking
diabetes mellitus
atrial fibrillation
• Strongly implicated in the risk of cardioembolic stroke but not other ischaemic stroke sub-types.[16]
comorbid cardiac conditions

DIAGNOSIS
• Several other cardiac conditions have been reported as potential causes of cardioembolism, with
varying degrees of evidence. These conditions include myocardial infarction with regional wall
motion abnormalities or decreased left ventricular ejection fraction, valvular disease, patent foramen
ovale with or without atrial septal aneurysm, mitral valve prolapse, prosthetic heart valve, and
cardiomyopathy.[17]
carotid artery stenosis

• Modestly associated with risk of first ever ipsilateral ischaemic stroke and strongly associated with
stroke recurrence after ipsilateral ischaemic stroke.[18] [19]
• Degree of stenosis is related to the risk of recurrent stroke.[20]
sickle cell disease

• Associated with vascular stenosis, brain ischaemia, and Moyamoya disease (vascular occlusion
affecting circle of Willis). In children, prophylactic transfusion based on transcranial Doppler ultrasound
criteria has been shown to lower subsequent stroke risk.[21]
dyslipidaemia
• Large prospective studies have shown that increased serum total cholesterol is modestly associated
with an increased risk of ischaemic stroke.[22]
• There are few studies on the association of low-density lipoprotein cholesterol with stroke, and the
results are conflicting.[17] A meta-analysis showed that increased high-density lipoprotein is protective
against ischaemic stroke.[23]
people with lower levels of education

• Stroke symptoms are more likely among those with lower income and lower educational attainment.[9]
Weak
African-American or Hispanic ancestry
• Have been associated with increased incidence of ischaemic stroke.[9] [24] Some, but not all, of
this increased risk is accounted for by higher prevalence of known vascular risk factors such as
hypertension and diabetes.
poor diet and nutrition

• Epidemiological studies show a relationship between decreased stroke risk and increased
consumption of fruits and vegetables,[25] decreased consumption of sodium,[26] and increased
consumption of potassium.[27]
• The effects of decreased sodium and increased potassium intake may be mediated by a lower risk of
hypertension.
physical inactivity
• Decreased physical activity has been associated with increased risk of ischaemic stroke.[28]
obesity
• Overweight and obese people have a modestly increased risk of ischaemic stroke.[29] [30]
DIAGNOSIS
alcohol abuse
• Heavy alcohol use is associated with an increased risk of ischaemic stroke.[31]
• Light to moderate alcohol consumption may be protective against ischaemic stroke.[31]
oestrogen-containing therapy
• A small increased risk of ischaemic stroke may be present in users of oral contraceptive pills; however,
studies are conflicting.[32]
• Clinical trials of oestrogen or oestrogen plus progestogen in post-menopausal women have shown an
increased incidence of ischaemic stroke.[33] [34]
illicit drug use

• Several drugs may influence stroke risk. Cocaine and other drugs may cause changes in blood
pressure or vasculitic-type changes in the intracranial circulation.
• Unsafe intravenous injections may lead to infective endocarditis with subsequent cardioembolism, or
paradoxical embolism of injected foreign material.
15
migraine
• Case-control studies show an elevated risk of stroke associated with migraine, particularly in younger
women and in those with migraine with aura.[35]
hyperhomocysteinaemia
• Prospective and case-control studies show that higher serum homocysteine levels are associated with
a higher risk of ischaemic stroke. However, a randomised trial of homocysteine lowering to prevent
stroke showed no benefit of therapy.[36] Subsequent studies with stroke as a secondary endpoint have
shown varying results.[37] [38] Therefore, although homocysteine is clearly a marker of ischaemic
stroke risk, it remains unclear whether homocysteine itself causes stroke.
elevated lipoprotein(a)
• Most studies of lipoprotein(a) and ischaemic stroke show increased risk with higher lipoprotein(a)
levels. Lipoprotein(a) levels can be lowered with niacin, but it is not known whether lipoprotein(a)
reduction reduces the risk of ischaemic stroke.
hypercoagulable states
• Elevated anti-cardiolipin or anti-beta2-glycoprotein-1 antibody levels have been associated with stroke.
• Hereditary conditions associated with venous thromboembolism (e.g., antithrombin III deficiency,
protein C deficiency, protein S deficiency, factor V Leiden mutation, or prothrombin gene mutations)
have not been found to be risk factors for ischaemic stroke[17] but are related to the risk of cerebral
venous sinus thrombosis.
• The possibility that hypercoagulable states may be more strongly associated with certain stroke sub-
groups, including stroke in young people, is plausible but has not been evaluated in large studies.
elevated C-reactive protein

• Associated with an increased risk of stroke after controlling for other risk factors.[39] Whether it directly
causes stroke or is merely a marker of risk is uncertain.
aortic arch plaques

DIAGNOSIS
• Aortic arch plaques may be a risk factor for recurrent stroke and death. In cases of cryptogenic
strokes, further diagnostic tests are warranted to search for large aortic plaques.[40]
History & examination factors

Key diagnostic factors
vision loss or visual field deficit (common)
• Monocular vision loss may occur and is often transient. This is a common early warning signal
for cervical carotid stenosis. It is not necessarily a sign of cerebral stroke; however, it should be
recognised and investigated with the same urgency.
• Vision loss may occur in patients with posterior circulation ischaemia.
• When visual field loss is unilateral, this sign may reflect either carotid or vertebrobasilar ischaemia,
whereas bilateral visual field loss is usually due to vertebrobasilar ischaemia.
weakness (common)
• Complete or partial loss of muscle strength in face, arm, and/or leg is a typical presentation of stroke.
• Weakness of all 3 suggests deep hemispheric involvement, although this may not differentiate stroke
mechanism.
• As with most stroke signs and symptoms, bilateral involvement is uncommon and may reflect
alternative aetiologies.
• Hemiparesis is associated with lacunar strokes.
aphasia (common)
• Impairment in any language function, either expressive or receptive, is a sign of dominant hemispheric
ischaemia.
impaired co-ordination (ataxia) (common)

• In the absence of muscle weakness, ataxia points to ischaemia involving the cerebellum or its
connections with the rest of the brain.
• Posterior circulation strokes are more commonly associated with difficulty with fine motor co-ordination
and gait.
Other diagnostic factors

history of transient ischaemic at tack (TIA) (common)
• More than half the patients presenting with stroke related to a cervical carotid artery atherosclerosis
have a history of TIA. Conversely, patients with a history of TIA are at a significant risk of subsequent
stroke. Most of these strokes occur within days of the TIA; a pooled analysis showed that 5% of TIA
patients have a stroke within 2 days.[53]
sudden onset of symptoms (common)

• Stroke symptoms often start suddenly over seconds to minutes and may worsen in a step-wise
fashion, fluctuate, or stutter.
• Slowly progressive symptoms often reflect other aetiologies, such as intracerebral haemorrhage.
• It is important to differentiate multiple, step-wise worsening from a gradual decline.
DIAGNOSIS
negative symptoms (i.e., loss of function) (common)
• Stroke often presents with negative symptoms such as visual loss, numbness, or weakness.
• Positive symptoms such as marching paraesthesias, visual hallucinations, and abnormal motor
manifestations are more likely to be related to complicated migraine or seizure. There are occasional
exceptions to the rule.
altered sensation (common)

• Patients often describe sensory loss and paraesthesias as numbness.
headache (common)
• Although headache is not uncommon in acute stroke, it should alert the physician to the possibility
of other pathologies such as intracerebral haemorrhage (may be insidious and gradually increasing),
subarachnoid haemorrhage (sudden onset with gradual moderation, "most severe headache of my
life"), intracranial hypertension (which may be caused by cerebral venous sinus thrombosis, space-
occupying lesion), or complicated migraine.
diplopia (common)
• May occur in patients with posterior circulation ischaemia.
17
sensory loss (common)
• Unilateral sensory loss on neurological examination may involve some or all primary modalities.
• Cortical sensory loss usually impairs fine sensory processing abilities such as 2-point discrimination,
graphaesthesia, or stereognosis.
dysarthria (common)
• This sign may accompany facial weakness or cerebellar dysfunction and is usually due to posterior
circulation ischaemia, but may be due to a lacunar infarct.
ga ze paresis (common)
• Often horizontal and unidirectional.
• More common with anterior circulation strokes.
• Wrong-way eye deviation (i.e., gaze deviation away from the side of the brain lesion, towards the
hemiparetic side) should prompt consideration of seizure but can also occur with strokes affecting the
pons or thalamus.
• Horner's syndrome suggests ipsilateral carotid dissection.
arrhythmias, murmurs, or pulmonary oedema (common)

• Associated with cardiac comorbidities, which predispose patients to stroke disease.
• Of particular significance is atrial fibrillation, which increases the patient’s risk for cardioembolic
ischaemic stroke. Therefore, all stroke patients should be assessed for this particular cardiac
arrhythmia with routine non-invasive monitoring and in all eligible patients extended monitoring should
be offered after stroke to increase the chance of detection of paroxysmal atrial fibrillation and earlier
initiation of treatment with anticoagulants.[54]
vertigo/dizziness (uncommon)
• This is a symptom of posterior circulation ischaemia. Although typically reported as a spinning
sensation, a feeling like being on a ship in choppy seas also describes vertigo.
• It is often associated with nystagmus.
DIAGNOSIS
nausea and/or vomiting (uncommon)

• This symptom may be due to posterior circulation ischaemia, or reflect increased intracranial pressure.
neck or facial pain (uncommon)

• May be associated with arterial dissection.
miosis, ptosis, and facial anhidrosis (hemilateral) (uncommon)

• Horner's syndrome may be associated with posterior circulation strokes.
altered level of consciousness/coma (uncommon)

• Reduced level of alertness may accompany large anterior circulation, thalamic, bihemispheric, or brain
stem strokes.
• This sign should prompt a higher level of urgency from both diagnostic (rule out haemorrhage) and
management (breathing and airway protection) points of view.
• Coma is more common with brain stem ischaemia.
• Other conditions mimicking stroke, such as seizures, should be ruled out in these patients.
confusion (uncommon)
• This is common, especially in older people with previous strokes or cognitive dysfunction.
• Receptive (Wernicke's) aphasia should be differentiated from confusion, because aphasia is a specific
sign of dominant-hemisphere ischaemia.
DIAGNOSIS
19
Diagnostic tests
1st test to order
Test Result
CT head hypoat tenuation
(darkness) of the brain
• All patients with transient ischaemic attack or possible ischaemic
parenchyma; loss of
stroke should initially undergo a CT scan of the brain to rule out
grey mat ter-white mat ter
intracranial haemorrhage.
differentiation, and
[Fig-3]
sulcal effacement;
• Most important test, needed to differentiate haemorrhagic from hyperat tenuation
ischaemic stroke. This test is used mainly to rule out haemorrhage (brightness) in an artery
rather than to diagnose stroke, as an essential step in acute stroke indicates clot within the
therapy.[55] vessel lumen
• In many cases, the CT is normal within the first few hours of an
ischaemic stroke.[56]
MRI brain acute ischaemic infarct
appears bright on
• MRI of the brain, particularly with diffusion-weighted and gradient-
diffusion-weighted
echo sequences, provides more accurate information about the
imaging; at later stages,
stroke lesion compared with CT, clearly highlights the area of
ischaemic infarct, and may provide further clues about the cause(s). T2 images may also show
increased signal in the
[Fig-2]
ischaemic territory
[Fig-1]
• However, in many medical centres around the world, MRI is not
available.
• Has higher sensitivity for infarction and equivalent sensitivity for
haemorrhage compared with CT.[57]
• Contraindicated in patients with certain metallic implants such as
pacemakers.
• Some specialised stroke centres are using MRI as the initial imaging
of choice, replacing CT.
DIAGNOSIS
• May be implemented in the sub-acute phase after CT in some

centres.
serum glucose may exclude hypo/
hyperglycaemia
• To exclude hypoglycaemia as a cause for focal neurological signs.
• Hyperglycaemia has been associated with poor outcome[58] and risk
of haemorrhagic transformation of ischaemic stroke.[59] [60]
• Every patient with transient ischaemic attack or stroke should be
screened for diabetes mellitus by measuring fasting plasma glucose
or haemoglobin A1c, or with an oral glucose tolerance test.[61]
serum electrolytes may exclude electrolyte
disturbance
• To exclude electrolyte disturbance as a cause for focal neurological
signs.
serum urea and creatinine may exclude renal failure
• Renal failure may be a potential contraindication to some stroke
interventions.
cardiac enzymes may exclude myocardial
infarction
• Stroke may be associated with concomitant myocardial infarction.
Test Result
ECG may exclude arrhythmia or
ischaemia
• Performed to exclude cardiac arrhythmia or ischaemia, which are
relatively common in ischaemic stroke.
• Present diagnostic protocols suggest a minimum of 24 hours of ECG
monitoring after an ischaemic stroke to exclude atrial fibrillation.
However, it has been found that ECG monitoring along with insertable
cardiac monitor was superior to conventional ECG monitoring in
diagnosing atrial fibrillation in cases of cryptogenic stroke.[49]
• In addition, one significant issue is that in patients with cryptogenic
stroke or transient ischaemic attack who are 55 years old or older,
non-invasive ambulatory ECG with a target of 30 days should
be utilised because this enables clinicians to diagnose and treat
paroxysmal atrial fibrillation.[50]
FBC may exclude anaemia and
thrombocytopenia
• Used to detect conditions that may be potential contraindications for
some acute stroke treatments and interventions. Excludes anaemia
or thrombocytopenia prior to possible initiation of thrombolytics,
anticoagulants, or antithrombotics.
prothrombin time and PTT (with international normalised ratio) may show coagulopathy
• If patient has no history of anticoagulant use, or of coagulopathy or a
condition that may lead to it, then thrombolysis does not need to be
delayed until the test results are available.[51]
DIAGNOSIS
21
Other tests to consider
Test Result
serum toxicology screen may exclude alcohol and
drug abuse
• Performed in selected patients if suspicion of ingestion of toxic
substances. Signs and symptoms may mimic stroke.
CXR normal; or cardiomegaly,
aortic dissection,
• In the presence of cardiopulmonary signs or symptoms, a CXR can
pneumonia
detect other relevant conditions.
CT or magnetic resonance angiography identifies arterial
occlusion or stenosis
• CT angiography preferably, or magnetic resonance angiography,
should be performed in all patients with acute ischaemic stroke and
suspicion of a large vessel occlusion who would be candidates for
endovascular thrombectomy.
CT or magnetic resonance venography identifies venous infarcts
• If routine imaging studies fail to show arterial occlusion, and if the
infarct imaging and clinical presentation show characteristics of
venous stroke (e.g., ischaemic tissue not conforming to a vascular
territory, severe haemorrhagic transformation and/or oedema,
intractable seizures at presentation, signs of increased intracranial
pressure), then patency of cerebral venous sinuses can be assessed
by CT or MR venography.
carotid ultrasound identifies cervical artery
occlusion or critical
• More frequently performed in the sub-acute stage to investigate for
stenosis
carotid stenosis.
transcranial Doppler ultrasound may reveal intracranial
artery occlusion or
• May be used to identify arterial occlusion of the major arterial
critical stenosis
branches of the circle of Willis.
• Spatial resolution is limited compared with CT and magnetic
resonance angiography.
DIAGNOSIS
conventional (invasive) angiography vascular occlusion or

• Not typically indicated in acute stroke unless a simultaneous stenosis, vasculitis,
arterial dissection,
endovascular intervention, such as intra-arterial thrombolysis or clot
reversible cerebral
retrieval, is contemplated.
vasoconstriction
syndrome, Moyamoya
disease (vascular
occlusion affecting circle
of Willis), fibromuscular
dysplasia
Emerging tests
Test Result
CT- or MRI-perfusion-weighted imaging identifies cerebral
regions with reduced
• Has been proposed as a means of selecting patients, presenting
blood flow that may be
beyond 4.5 hours, who have hypoperfused but still viable tissue.
at risk for subsequent
• These imaging methods are promising but have not yet been fully
infarction
validated for patient selection for re-perfusion therapies.[52]
[Fig-4]
DIAGNOSIS
23
Differential diagnosis
Condition Differentiating signs / Differentiating tests

symptoms
Intracerebral • No symptoms or signs • CT or MRI demonstrates
haemorrhage reliably distinguish haemorrhage
haemorrhagic stroke from (hyperattenuation).
ischaemic stroke.
• Haemorrhagic stroke is
more often associated
with reduced level of
consciousness and signs
of increased intracranial
pressure than ischaemic
stroke.
Transient ischaemic • Transient neurological • CT or MRI may be normal or

at tack symptoms last less than 24 may reveal evidence of older
hours, with no evidence of infarcts.
acute infarct.
Hypertensive • The combination of • Cerebral oedema on CT or

encephalopathy headache, cognitive MRI.
abnormalities or decreased
level of consciousness,
and hypertension
significantly above patient's
baseline blood pressure
indicates hypertensive
encephalopathy. Other
possible signs/symptoms
include visual changes or
loss, or signs of increased
intracranial pressure.[46]
DIAGNOSIS
Hypoglycaemia • There may be a history of • Low serum glucose at time

diabetes with use of insulin of symptoms.
or insulin secretagogues.
• Decreased level of
consciousness.
Complicated migraine • Repetitive history of similar • MRI shows no evidence of

events; preceding aura, infarction.
headache in a marching
pattern differentiates
complicated migraine.[46]
• Stroke often presents with
negative symptoms (e.g.,
visual loss, numbness, or
weakness).
• Positive symptoms (e.g.,
marching paraesthesias,
visual hallucinations,
and abnormal motor
manifestations) are more
Condition Differentiating signs / Differentiating tests

symptoms
likely with complicated
migraine.
Seizure and postictal • Hx seizures; witnessed • Electroencephalogram

deficits seizure followed by postictal confirms evidence of seizure.
deficits: for example, • MRI shows no evidence of
drowsiness and tongue- infarction.
biting.[46]
• Wrong-way eye deviation
(i.e., gaze deviation
away from the side of the
brain lesion, towards the
hemiparetic side) should
prompt consideration of
seizure but can also occur
with strokes affecting the
pons or thalamus.
Conversion and • Neurological signs and • MRI shows no evidence of

somatisation disorders symptoms do not fit a infarction.
vascular territory.
• No cranial nerve deficits.
• Additionally, conversion
disorder displays multiple
signs that are neurologically
inconsistent.
Wernicke's • History of alcohol abuse. • Decreased blood thiamine

encephalopathy • Irritability, confusion, and level and successful
delirium common presenting therapeutic trial of thiamine.
features.
Brain tumour • Symptoms and signs more • CT head demonstrates

likely to have been on-going. lesion or lesions.
DIAGNOSIS
• May be history of cancer if
metastatic lesion causing
symptoms.
25
Ischaemic stroke Treatment
Step-by-step treatment approach

The goals of treatment of acute ischaemic stroke are to restore blood flow, support energy metabolism
in ischaemic tissue, treat complications of stroke-related oedema, and prevent common acute medical
complications. Rapid evaluation and diagnosis is the cornerstone of successful ischaemic stroke therapy.
Computed tomography (CT) or magnetic resonance imaging (MRI) scan is mandatory to exclude
intracerebral haemorrhage and stroke mimics. The absence of signs on CT does not exclude acute
ischaemic stroke. Following assessment of airway, breathing, and circulation, the next step is to consider
whether reperfusion can be achieved.
Intravenous thrombolysis
Alteplase, a recombinant tissue plasminogen activator (r-tPA), promotes thrombolysis and thereby
re-canalisation and re-perfusion. Early administration of alteplase to appropriate patients is
recommended.[51] Results of clinical trials utilising alteplase for thrombolysis in patients with acute
ischaemic stroke and no contraindications have suggested that the window of opportunity for treatment
of these patients is 4.5 hours after the onset of neurological symptoms.[51] [62] [63] 1[A]Evidence Early
treatment is especially important in patients with severe acute stroke.[64] Goal time between emergency
department arrival and start of CT scan is 25 minutes, and from emergency department arrival to initiation
of intravenous r-tPA (if indicated) is 60 minutes.[46]
Information regarding the benefits and risks of r-tPA treatment should be given to the patient, if
competent, or to a surrogate decision-maker, if present. Verbal or written consent should be obtained
if feasible. In the frequent situation where the patient is not competent to make medical decisions, and
family or a surrogate decision-maker cannot be identified or approached in a timely manner, the physician
should substitute his or her judgement. Decision-makers should be informed of the overall 6% risk of
brain haemorrhage, of which approximately half are fatal. They should also be informed that despite this
risk people treated with r-tPA are more likely to do better. Overall 1 in 8 people treated with r-tPA have a
complete or near-complete recovery who otherwise would have been disabled; this statistic is the number
needed to treat.[65]
Contraindications to intravenous thrombolysis with r-tPA

The following are contraindications to r-tPA treatment from the American Heart Association/American
Stroke Association (AHA/ASA) guidelines:[51]
• Onset of symptoms >4.5 hours

• CT reveals acute acute intracranial haemorrhage
• There is history of head trauma or prior stroke in the previous 3 months
• There is history of previous intracranial haemorrhage
• There is history of intracranial/intraspinal surgery within 3 months
• The symptoms of stroke are suggestive of subarachnoid haemorrhage
• Patients with platelets <100 000/mm3, international normalised ratio (INR) >1.7, activated PTT
(aPTT) >40 seconds, or prothrombin time >15 seconds
TREATMENT
• There is history of gastrointestinal malignancy or recent bleeding event in the previous 21 days
• There is history of major surgery or serious trauma in the previous 14 days
• Patient has received a dose of low-molecular-weight heparin within the previous 24 hours
• Patient is taking direct thrombin inhibitors or direct factor Xa inhibitors unless laboratory tests such
as aPTT, INR, platelet count, ecarin clotting time, thrombin time, or appropriate direct factor Xa
activity assays are normal or the patient has not received a dose of these agents for >48 hours
(assuming normal renal metabolising function)
• There is evidence of active bleeding on examination
• There are symptoms consistent with infective endocarditis
• There is known or suspected association between the acute ischaemic stroke and aortic arch
dissection
• Patient is taking antiplatelet agents that inhibit the glycoprotein IIb/IIIa receptor
• There is history of an intra-axial intracranial neoplasm.
Candidates for intravenous thrombolysis with r-tPA

The AHA/ASA guidelines state that the eligibility recommendations for treating with r-tPA are:[51]
• Within 3 hours or patient last known well or at baseline state:
• Medically eligible patients ≥18 years of age or <80 and >80 years of age
• Patients with severe stroke symptoms or mild but disabling stroke symptoms
• Within 3 to 4.5 hours or patient last known well:
• Patients ≤80 years of age

• Those without a history of both diabetes mellitus and stroke
• Those with a baseline National Institutes of Health (NIH) Stroke Scale score ≤25
• Those not taking any oral anticoagulants
• Those without imaging evidence of ischaemic injury involving more than one third of the
middle cerebral artery territory
• Patients whose blood pressure can be lowered safely to <185/110 mmHg with antihypertensive
agents
• Patients with initial glucose levels >2.8 mmol/L (>50 mg/dL)
• Patients with early ischaemic changes on non-contrast computed tomography of mild to moderate
extent (other than frank hypodensity)
• Patients who have had antiplatelet monotherapy or combination therapy before stroke, provided
the benefit of alteplase outweighs the possible increased risk of symptomatic intracerebral
haemorrhage
• Patients with end-stage renal disease on haemodialysis and normal aPTT.
Additional recommendations for treatment with r-tPA can be found in the AHA/ASA guidelines.[51]
Administration of r-tPA should not be delayed by additional tests unless a specific contraindication
is suspected and must be ruled out. Blood glucose should be normalised before initiating r-tPA
treatment.[51]
Caution should be exercised in treating a patient with major deficits, as the likelihood of favourable
outcome is reduced and there is increased risk of haemorrhage following thrombolysis in these
patients.[51] [66] A meta-analysis found that patients aged 80 years or over presenting with new-onset
TREATMENT
neurological deficits, who are also candidates for r-tPA, appear to have a lower probability of a favourable
outcome and a higher mortality rate compared with younger patients. However, the rate of symptomatic
intracranial haemorrhage was not significantly increased.[67]
27
Aspirin
Ischaemic stroke patients should receive aspirin.[51] Aspirin should be given to patients who have
received r-tPA and to those who are not eligible for r-tPA. However, if r-tPA is administered, aspirin
should not be started for 24 hours, and only then after a head CT shows the absence of intracranial
haemorrhage.[51] [68] Although studies of aspirin for acute ischaemic stroke have shown a trend
towards better outcomes in the aspirin arm,[69] [70] a study examining early (i.e., within 24 hours)
administration of aspirin in acute ischaemic stroke patients receiving r-tPA did not show any significant
improvements in outcomes at 3 months.[68] Furthermore, early administration of aspirin was associated
with a significant increase in risk of symptomatic intracerebral bleeding. Non-aspirin antiplatelet drugs,
including dipyridamole, clopidogrel, and platelet glycoprotein IIb/IIIa inhibitors, have not been studied
in acute stroke and, therefore, in general are not indicated. However, these medicines are useful in the
secondary prevention of stroke.[71]
Endovascular interventions
In certain carefully selected patients with acute ischaemic stroke, use of endovascular interventions in
addition to intravenous r-tPA can provide clinical benefits. As is the case with intravenous r-tPA, initiation
of endovascular interventions should be carried out as early as possible. Initiation within the first 6 hours
of ischaemic stroke onset is likely to result in a more favourable outcome with these interventions.[51]
Endovascular interventions include intra-arterial thrombolysis and mechanical clot-removing devices,

such as stent retrievers. The AHA/ASA guidelines recommend the use of stent retrievers over intra-
arterial thrombolysis and other mechanical thrombectomy devices (e.g., concentric retrievers) as first-
line endovascular therapy for acute ischaemic stroke; however, devices other than stent retrievers may
be reasonable in some circumstances.[51] The use of a proximal balloon guide catheter or large bore
distal catheter, rather than a cervical guide catheter alone, in conjunction with stent retrievers may also be
useful in certain carefully selected patients.[51] Furthermore, it may be reasonable to use an adjunctive
intervention (e.g., intra-arterial thrombolysis) to achieve acceptable reperfusion, if it is used within 6 hours
of symptom onset.
Candidates for endovascular interventions

The AHA/ASA guidelines state that patients who are eligible for r-tPA should be treated with r-tPA even if
they are potential candidates for endovascular therapy with a stent retriever.[51] Observing patients for a
clinical response to intravenous r-tPA prior to use of endovascular therapy is not required.
The AHA/ASA guidelines suggest that patients who meet all of the following criteria should be treated with
a stent retriever:[51]
• Have a pre-stroke modified Rankin disability scale score 0 to 1

• Have causative occlusion of the internal carotid artery or proximal middle cerebral artery (M1)
• Aged ≥18 years
• Have a NIH Stroke Scale score ≥6
• Have an Alberta Stroke Program Early CT score (ASPECTS) ≥6
TREATMENT
• Can begin endovascular therapy (groin puncture) within 6 hours of symptom onset.
Although there is a lack of evidence for stent retrievers in ischaemic stroke patients outside of these
criteria, they may be considered for use in those with anterior circular occlusion who cannot be treated
with intravenous r-tPA, or those with occlusion of other vessels, such as the M2 or M3 portion of the
middle cerebral artery, anterior cerebral arteries, vertebral arteries, basilar artery, or posterior cerebral
arteries. They may also be considered for patients who are aged <18 years, or have a modified Rankin
disability scale score >1, or an ASPECTS <6, if initiated within 6 hours of symptom onset, but the potential
benefits are unclear as there is a lack of evidence in these patients.
Initial treatment with intra-arterial thrombolysis may be considered for carefully selected patients with
major ischaemic strokes of <6 hours’ duration with causative occlusion of the middle cerebral artery,[72]
or those with contraindications or an incomplete response to r-tPA. However, the evidence for intra-arterial
thrombolysis is weak, and there are no intra-arterial thrombolytic interventions approved for use in stroke.
Anticoagulation
Urgent anticoagulation in unselected ischaemic stroke patients, with the goal of improving acute stroke
outcomes, is generally not recommended. Meta-analyses fail to show reduction in stroke disability
in acute ischaemic stroke patients treated with anticoagulants but do show an increase in the risk of
haemorrhagic transformation of stroke, particularly in patients with larger stroke volumes.[73]
There is still inadequate evidence to guide treatment decisions about the optimal time of anticoagulation
treatment in patients with acute transient ischaemic attack or ischaemic stroke and an indication for
anticoagulation. Some experts suggest to initiate anticoagulation in atrial fibrillation patients between 1
and 12 days after an ischaemic stroke, depending on stroke severity, using the 1-3-6-12 days approach
with re-institution of anticoagulation in patients with:[74]
• Transient ischaemic attack: 1 day after acute event

• Small, non-disabling infarct: 3 days after acute event
• A moderate stroke: 6 days after acute event
• Large infarcts involving large parts of the arterial territory: 12 days after acute event.
Anticoagulation is, however, first-line therapy for cerebral venous sinus thrombosis (as identified on
imaging), even in the presence of haemorrhagic transformation of the infarction.[66] Anticoagulation
should be continued for 3 to 6 months. In the absence of progressive symptoms, patients may be
transitioned to warfarin in the acute period, with target INR 2.0 to 3.0. Aspirin and r-tPA are not indicated
in these patients.
Supportive care
At the same time as the acute evaluation for reperfusion therapies, the following steps should be taken:
• Support blood oxygenation. Supplemental oxygen should be provided only when blood oxygen
saturation is <94%. Liberal use of oxygen is associated with increased mortality in acutely ill
patients.[75] [76]Patients with decreased level of consciousness or refractory hypoxaemia may
require intubation with mechanical ventilation.[51] [77]
[VIDEO: Tracheal intubation animated demonstration ]
[VIDEO: Bag-valve-mask ventilation animated demonstration ]

• Support systemic blood pressure (BP). Management of arterial BP in acute ischaemic stroke
TREATMENT
remains controversial because of conflicting evidence and a lack of large controlled clinical trials.
Many patients with ischaemic stroke have elevated BP at presentation. Lowering BP could reduce
cerebral perfusion pressure and promote stroke extension.[81]
• Normalise blood glucose levels. Hypoglycaemia can cause brain injury and should be avoided.
Hyperglycaemia has been associated with poor outcome[58] and risk of haemorrhagic
29
transformation of ischaemic stroke.[59] [60] Treatment of significantly elevated blood glucose is
recommended despite inconclusive evidence.[82] [83] [84]
• Reduce fever. Fever has been associated with worse stroke outcome.[85] Treatment of fever is
therefore reasonable, although not yet shown to be effective by controlled trials.[51] [86] [87] [88]
These steps, while not shown to be effective by clinical trials, may retard stroke evolution or prevent stroke
extension by optimising energy substrate delivery and tissue energy metabolism.
Following emergency department evaluation and treatment, patients with ischaemic stroke should be
transferred to a dedicated stroke unit. These units have been shown in controlled and non-controlled trials
to improve stroke functional outcome and survival.[89] Stroke units should have multi-disciplinary teams
which include physicians, nursing staff, and rehabilitation specialists with expertise in stroke. Improved
supportive care, avoidance of complications such as infection, and earlier initiation of rehabilitation
therapy are among the mechanisms by which stroke units are hypothesised to produce better outcomes.
Nutritional support, rehabilitation therapy (physical, occupational, and/or speech therapy as indicated),
prevention of aspiration (swallowing assessment), and prevention of venous thromboembolism (VTE) are
all required in the sub-acute phase of hospital care.
Swallowing impairment is common in stroke and is associated with an increased risk of aspiration
pneumonia[90] and death.[91] Guidelines support the use of a bedside swallow test before eating or
drinking but do not provide specifics on test administration and interpretation.[51] A reasonable approach
is to withhold oral intake if there is coughing or a wet voice after swallowing a small cup of water. Patients
who cannot take nutrition orally should be hydrated with isotonic fluids (to decrease risk of brain oedema)
and receive enteral feeding by nasogastric, nasoduodenal, or percutaneous gastrostomy tube.
VTE is the cause of about 10% of stroke deaths.[92] VTE prophylaxis should be provided to non-
ambulatory stroke patients, even though most of the evidence for VTE prophylaxis comes from
controlled trials in non-stroke populations.[93] Anticoagulants should be used except when haemorrhagic
transformation is present, in which case pneumatic compression devices may be used instead.[94]
Early mobilisation of patients is also recommended in stroke patients. This may decrease risk of venous
thromboembolism by reducing venous stasis, but this has not been demonstrated in controlled trials.[95]
There is insufficient evidence to recommend the use of drugs that affect nitric oxide production (ie., nitric
oxide donors, L-arginine, or nitric oxide synthase inhibitors) in acute stroke.[96] A Cochrane review has
shown that cerebrolysin, a mixture of peptides derived from pig brain tissue, performs no better than
placebo in terms of all-cause death when given to people with acute ischaemic stroke within 48 hours
of stroke onset. There are also concerns about the increase of serious adverse events with cerebrolysin
use in people with acute ischaemic stroke.[97] While it is commonly used in some countries (e.g., China,
Russia), it is not available in other locations, including the US, Europe, and the UK.
Treatment details overview

Please note that formulations/routes and doses may differ between drug names and brands, drug
TREATMENT
formularies, or locations. Treatment recommendations are specific to patient groups: see disclaimer
Acute ( summary )
without cerebral venous sinus
thrombosis
presentation within 1st alteplase (recombinant tissue

4.5 hours and no plasminogen activator or r-tPA)
contraindication to
thrombolysis
adjunct aspirin 24 hours after r-tPA
adjunct endovascular intervention (stent retriever)
plus supportive care
plus swallowing assessment
adjunct VTE prophylaxis + early mobilisation
presentation after 4.5 1st aspirin

hours or contraindication
to thrombolysis
with cerebral venous sinus

thrombosis
1st anticoagulation
TREATMENT
31
Treatment options
Please note that formulations/routes and doses may differ between drug names and brands, drug
formularies, or locations. Treatment recommendations are specific to patient groups: see disclaimer
TREATMENT
Acute
without cerebral venous sinus
thrombosis
presentation within 1st alteplase (recombinant tissue

4.5 hours and no plasminogen activator or r-tPA)
contraindication to
Primary options
thrombolysis
» alteplase: 0.9 mg/kg total dose
intravenously, administer 10% of dose as a
bolus, with the remaining 90% infused over 1
hour, maximum 90 mg total dose
» Intravenous alteplase (r-tPA) promotes

thrombolysis, which may result in reperfusion of
ischaemic but still salvageable brain tissue.
» Results of clinical trials utilising alteplase for

thrombolysis in patients with acute ischaemic
stroke and no contraindications suggest that
the window of opportunity for treatment of
these patients is 4.5 hours after the onset
of neurological symptoms.[51] [62] [63]
1[A]Evidence Early treatment is especially
important in patients with severe acute
stroke.[64] In the frequent situation where the
onset of symptoms was not witnessed, the
time of onset must be presumed to be the time
at which the patient was last witnessed to be
normal.
» Criteria for use include measurable

neurological deficit and positive computed
tomography head; no recent history of head
trauma, myocardial infarction, gastrointestinal or
urinary tract haemorrhage; no recent surgery;
no previous history of intracranial haemorrhage;
acceptable blood pressure, platelet count,
international normalised ratio, and glucose
levels; no seizures.
» Guidelines from the American Heart

Association/American Stroke Association (AHA/
ASA) state that the eligibility recommendations
for treating with r-tPA are:[51]
» Within 3 hours or patient last known well or

at baseline state: medically eligible patients
≥18 years of age or <80 and >80 years of age;
severe stroke symptoms or mild but disabling
stroke symptoms.
TREATMENT
» Within 3 to 4.5 hours or patient last known

well: patients ≤80 years of age; those without
a history of both diabetes mellitus and stroke;
those with a baseline National Institutes of
Health Stroke Scale score ≤25; those not taking
33
Acute
any oral anticoagulants; those without imaging
evidence of ischaemic injury involving more than
one third of the middle cerebral artery territory.
» Additional recommendations for treatment

with r-tPA can be found in the AHA/ASA
guidelines.[51]
» Cerebral venous sinus thrombosis is a

contraindication, and orolingual oedema is a rare
but potentially serious complication.
adjunct aspirin 24 hours after r-tPA
Treatment recommended for SOME patients in
selected patient group
Primary options
» aspirin: 300 mg orally once daily
» Ischaemic stroke patients should receive

aspirin.[51] Patients who are administered
alteplase (r-tPA) should not start aspirin for 24
hours after r-tPA, and only then after a head
computed tomography shows the absence of
intracranial haemorrhage.[51] [68] [98]
» Two randomised trials of aspirin for acute

ischaemic stroke have shown a trend towards
better outcomes in the aspirin arm.[69] [70]
» Non-aspirin antiplatelet drugs, including

dipyridamole, clopidogrel, and platelet
glycoprotein IIb/IIIa inhibitors, have not been
studied in acute stroke and therefore in general
are not indicated. However, these drugs may be
useful in the secondary prevention of stroke.[71]
adjunct endovascular intervention (stent retriever)
» Stent retrievers used in conjunction with
intravenous r-tPA can provide clinical benefits
in certain carefully selected patients with
acute ischaemic stroke.[99] [100] [101] [102]
[103] [104] [105] [106] The American Heart
Association/American Stroke Association
recommends the use of stent retrievers over
intra-arterial thrombolysis and other mechanical
thrombectomy devices (e.g., concentric
retrievers) as first-line endovascular therapy for
acute ischaemic stroke; however, devices other
TREATMENT
than stent retrievers may be reasonable in some

circumstances.[51]
» Initiation of endovascular interventions should

be carried out as early as possible, ideally within
the first 6 hours of ischaemic stroke onset.
Acute
» Patients meeting all of the following criteria
can be treated with a stent retriever: have a pre-
stroke modified Rankin disability scale score 0
to 1; have causative occlusion of the internal
carotid artery or proximal middle cerebral artery
(M1); aged ≥18 years; have a National Institutes
of Health Stroke Scale score ≥6; have an Alberta
Stroke Program Early CT score (ASPECTS)
≥6; and can begin endovascular therapy (groin
puncture) within 6 hours of symptom onset.[51]
» Stent retrievers may be considered for

ischaemic stroke patients outside of these
criteria if used within 6 hours of symptom
onset: for example, patients with anterior
circular occlusion who cannot be treated with
intravenous r-tPA; those with occlusion of other
vessels such as the M2 or M3 portion of the
middle cerebral artery, anterior cerebral arteries,
vertebral arteries, basilar artery, or posterior
cerebral arteries; or those with an ASPECTS
<6.[51] However, this is not supported by
evidence.
» Proximal balloon guide catheter or a large

bore distal catheter, rather than a cervical
guide catheter alone, in conjunction with stent
retrievers may also be useful in certain carefully
selected patients.[51] An adjunctive intervention
(e.g., intra-arterial thrombolysis) may also be
useful to achieve acceptable reperfusion, if
it is used within 6 hours of symptom onset.
However, there are no intra-arterial thrombolytic
interventions approved for use in stroke.
Treatment recommended for ALL patients in
» Controlled clinical trials have shown that
admission to a dedicated stroke unit, in
comparison to admission to a general medical/
surgical service, is associated with improved
survival and less disability at 1 year.[89]
Stroke units should include multi-disciplinary
teams including physicians, nursing staff,
and rehabilitation specialists with expertise in
stroke. Improved supportive care, avoidance
of complications such as infection, and earlier
initiation of rehabilitation therapy are among
the mechanisms by which stroke units are
hypothesised to produce better outcomes.
TREATMENT
» Supplemental oxygen should be provided only

when blood oxygen saturation is <94%. Liberal
use of oxygen is associated with increased
mortality in acutely ill patients.[75] [76]Patients
with decreased level of consciousness or
35
Acute
refractory hypoxaemia may require intubation
with mechanical ventilation.[51] [77]
[VIDEO: Tracheal intubation

animated demonstration ]
[VIDEO: Bag-valve-mask ventilation

» Management of arterial blood pressure (BP)
in acute ischaemic stroke remains controversial
because of conflicting evidence and a lack of
large controlled clinical trials. Many patients
with ischaemic stroke have elevated BP at
presentation. Lowering BP could reduce
cerebral perfusion pressure and promote stroke
extension.[81]
» Hypoglycaemia can cause brain injury and

should be avoided. Hyperglycaemia has been
associated with poor outcome[58] and risk
of haemorrhagic transformation of ischaemic
stroke.[59] [60] Treatment of significantly
elevated blood glucose is recommended despite
inconclusive evidence.[82] [83] [84]
» Fever has been associated with worse stroke

outcome.[85] Treatment of fever is therefore
reasonable, although not yet shown to be
effective by controlled trials.[51] [86] [87] [88]
» Swallowing impairment is common in stroke
and is associated with an increased risk of
aspiration pneumonia[90] and death.[91]
Guidelines support the use of a bedside
swallow test before eating or drinking but do
not provide specifics on test administration and
interpretation.[51]
» A reasonable approach is to withhold oral

intake if there is coughing or a wet voice after
swallowing a small cup of water.
» Patients who cannot take nutrition orally should

receive fluids and enteral feeding by nasogastric,
nasoduodenal, or percutaneous gastrostomy
tube.
TREATMENT

Primary options
Acute
» heparin: 5000 units subcutaneously every
12 hours
-or-
» dalteparin: 5000 units subcutaneously once
daily
-or-
» enoxaparin: 40 mg subcutaneously once
daily
-or-
» pneumatic compression devices
--AND--
» early mobilisation
» Venous thromboembolism (VTE) is the cause

of about 10% of stroke deaths.[92]
» Prophylaxis against VTE should be provided

to non-ambulatory stroke patients; efficacy data
come predominantly from controlled trials in non-
stroke populations.[93]
» VTE prophylaxis may include heparins and

pneumatic compression devices.[95]
» Early mobilisation of patients is recommended,

but efficacy has not been demonstrated in
controlled trials. May decrease risk of venous
thromboembolism by reducing venous stasis.
presentation after 4.5 1st aspirin
hours or contraindication
Primary options
to thrombolysis
» aspirin: 300 mg orally once daily
» Ischaemic stroke patients should receive

aspirin.[51]
» Two randomised trials of aspirin for acute

ischaemic stroke have shown a trend towards
better outcomes in the aspirin arm.[69] [70]
» Non-aspirin antiplatelet drugs, including

dipyridamole, clopidogrel, and glycoprotein
IIb/IIIa inhibitors, have not been studied in
acute stroke and therefore in general are not
indicated. However, these drugs are useful in the
secondary prevention of stroke.[71]
TREATMENT

37
Acute

when blood oxygen saturation is <94%. Liberal
» Management of arterial blood pressure (BP)

in acute ischaemic stroke remains controversial
large controlled clinical trials. Many patients
extension.[81]



TREATMENT

swallow test before eating or drinking, but do
interpretation.[51]
Acute

tube.
Primary options
» heparin: 5000 units subcutaneously every

12 hours
-or-
» dalteparin: 5000 units subcutaneously once
daily
-or-
» enoxaparin: 40 mg subcutaneously once
daily
-or-
» pneumatic compression devices
--AND--
» early mobilisation
» Venous thromboembolism (VTE) is the cause

of about 10% of stroke deaths.[92]
» Prophylaxis against DVT should be provided

to non-ambulatory stroke patients; efficacy data
come predominantly from controlled trials in non-
stroke populations.[93]
» VTE prophylaxis may include heparins and

pneumatic compression devices.[95]
» Early mobilisation of patients is recommended,

but efficacy has not been demonstrated in
controlled trials. May decrease risk of venous
thromboembolism by reducing venous stasis.
with cerebral venous sinus
thrombosis
1st anticoagulation
Primary options
» heparin: consult specialist for guidance on

dosing
TREATMENT
OR
» warfarin: 2-10 mg orally once daily initially,

adjust according to INR (target 2.0 to 3.0)
39
Acute
» The use of unfractionated intravenous heparin
for venous sinus thrombosis, even in the
presence of haemorrhagic infarction, has been
recommended based on results from small
clinical trials.[66]
» Dosing recommendations are based on

a stroke-specific dosing scale shown to be
superior to usual physician care.[107]
» Intravenous heparin should be used with

caution because of its known association
with haemorrhagic conversion of ischaemic
stroke.[73]
» Anticoagulation should be continued for 3

to 6 months. In the absence of progressive
symptoms, patients may be transitioned
to warfarin in the acute period, with target
international normalised ratio (INR) 2.0 to 3.0.
» In the event of abrupt neurological change,

obtain head computed tomography and consider
ceasing heparin until haemorrhage is ruled out.
» Aspirin and alteplase (r-tPA) are not indicated

in these patients.

when blood oxygen saturation is <94%.Liberal
TREATMENT
Acute

» Management of arterial BP in acute
ischaemic stroke remains controversial
large controlled clinical trials.Many patients
extension.[81]


swallow test before eating or drinking but do
interpretation.[51]


tube.
TREATMENT
41
Ischaemic stroke Follow up
Recommendations
Monitoring
FOLLOW UP
Monitoring parameters for patients on alteplase (recombinant tissue plasminogen activator or r-tPA) as
per American Heart Association/American Stroke Association (AHA/ASA) guidelines:[51]
• Admit the patient to a stroke unit for monitoring

• Perform blood pressure and neurological assessments every 15 minutes during and after
intravenous r-tPA infusion for 2 hours, then every 30 minutes for 6 hours, then hourly until 24 hours
after intravenous r-tPA treatment
• If the patient develops severe headache, acute hypertension, nausea, or vomiting, or has a
worsening neurological examination, discontinue the infusion and obtain emergency CT scan
• Increase the frequency of BP measurements if a systolic BP is ≥180 mmHg or if a diastolic BP is
≥105 mmHg; administer antihypertensive medicines to maintain BP at or below these levels
• Delay placement of nasogastric tubes, indwelling bladder catheters, or intra-arterial pressure
catheters if the patient can be safely managed without them
• Obtain a follow-up CT or MRI scan at 24 hours after intravenous r-tPA before starting
anticoagulants or antiplatelet agents.
Further monitoring may be required for secondary prevention of ischaemic stroke. For example, cardiac
monitoring for atrial fibrillation should be carried out at initial assessment and continued throughout
treatment of acute stroke. The AHA/ASA guidelines recommend continuous cardiac monitoring for at
least the first 24 hours after stroke.[51] Further outpatient monitoring may be instituted in patients with
cryptogenic stroke and suspected paroxysmal arrhythmias, particularly if they had a short admission and
brief monitoring.
Patient instructions
Patients are encouraged to continue rehabilitation in a specialised stroke facility. Rehabilitation often
focuses on activities of daily living, mobility skills, communication skills, and psychological functioning,
and over time will help with improvement of initial symptoms.[115] Patients are advised that depression
may occur after stroke and if not treated will interfere with progress; seeking help at the sign of any
key symptoms is important. Lifestyle changes should include referral to smoking and alcohol cessation
programmes as necessary.
[Stroke Association: life after stroke]
All patients who have had ischaemic stroke or transient ischaemic attack who are capable of physical
exercise must be instructed to participate in at least 3 to 4 sessions of moderate to heavy exercise weekly
in order to decrease the risk factors for stroke.[61] Stroke patients with residual disability should be
referred to physiotherapists or cardiac rehabilitation professionals so they can participate in supervised
and goal-oriented rehabilitation.[61]
Complications
Complications Timeframe Likelihood
FOLLOW UP
deep venous thrombosis (DVT) short term medium
Motor weakness with lack of mobility causes venous stasis in the lower limbs, resulting in DVT.
Anticoagulation will reduce the risk of pulmonary embolism.[93]
seizure short term low
May occur with anterior circulation stroke affecting the pons or thalamus.
haemorrhagic transformation of ischaemic stroke short term low
Haemorrhagic conversion can occur in any ischaemic stroke, but is more common in larger infarcts
and those for which anticoagulation or alteplase (recombinant tissue plasminogen activator) has been
given.[51] Petechial bleeding may be relatively common and is frequently asymptomatic.[51]
r-tPA-related orolingual oedema short term low
Orolingual oedema can rarely complicate use of alteplase (recombinant tissue plasminogen activator or r-
tPA) and can sometimes require intubation for airway protection.
brain oedema and elevated intracranial pressure short term low
Patients with large infarctions affecting the cerebellum or middle cerebral artery are at risk of developing
oedema and elevated intracranial pressure. If left unchecked, the oedema compromises blood flow and
causes brain herniation, which is frequently fatal.
Cerebellar swelling from oedema may cause rapid elevations in pressure in the posterior fossa,
pressure on the brainstem anteriorly, upward or downward cerebellar herniation, or acute hydrocephalus
from compression of the fourth ventricle. Symptoms include obtundation, quadriparesis, oculomotor
abnormalities, or new facial palsy. Placement of an external ventricular drain or decompressive surgery
can be life-saving.[112] Transfer of patients with large cerebellar infarction to a hospital with 24-hour
availability of emergency neurosurgical consultation is indicated.
Decompressive hemicraniectomy should be considered for large hemispheric strokes causing deterioration
from mass effect. Consider decompressive hemicraniectomy in patients with large middle cerebral artery
(MCA) infarction covering all or a significant MCA territory (also recognised as malignant MCA ischaemic
infarct), and declining consciousness within 45 hours after stroke onset.[113] [114] In all patients with large
ischaemic infarcts with potential of brain swelling and herniation, neurosurgical consultation with focus
on decompressive hemicraniectomy should be secured. Neurosurgical intervention reduces mortality,
but survivors are frequently left with severe disability and poor quality of life. Surrogate decision-makers
should be made aware of this and the decision to undertake surgery should be made on a case-by-case
basis.
depression variable high
Depression is common after stroke, and may warrant treatment with psychotherapy or antidepressant
medicines.[111]
aspiration pneumonia variable low
43
Complications Timeframe Likelihood

Stroke-related dysphagia results in aspiration and subsequent pneumonia. A dysphagia screen should be
performed in stroke patients prior to oral intake.[51] When aspiration pneumonia occurs, the pneumonia
FOLLOW UP
should be treated with antibiotics and consideration given to whether enteral feeding is indicated.[51]
Prognosis
In 2013, a total of 3.3 million individuals died of ischaemic stroke worldwide. Between 1990 and 2010,
ischaemic stroke mortality decreased 37% in high-income countries and 14% in low- and middle-income
countries.[9] Stroke is a leading cause of serious long-term disability in the US.[9] Prognosis of functional
outcome can be reliably performed by well-validated prognostic scores like the ASTRAL score or the
iScore.[108] Intravenous thrombolysis and dedicated stroke units are the only interventions shown to improve
stroke outcome.
Common medical complications of stroke include aspiration pneumonia, depression, and deep vein
thrombosis.
A meta-analysis study on the efficacy of physiotherapy following stroke found that a variety of interventions
improved functional outcomes, even when they were applied late after stroke.[109]
Patients receiving recombinant tissue plasminogen activator (r-

tPA)
These patients are more likely to have a better outcome than non-r-tPA-treated patients, despite the 6% risk
of symptomatic intracranial haemorrhage. The number needed to treat to prevent 1 additional case of stroke-
related disability is approximately 8.[65] Newer research suggests that the number needed to treat to 'shift' a
patient 1 point on the modified Rankin disability scale is even lower (i.e., even in patients without complete or
near-complete recovery, r-tPA probably results in less severe disability).[110]
Ischaemic stroke Guidelines
Diagnostic guidelines
Europe
Stroke and transient ischaemic at tack in over 16s: diagnosis and initial
management
Published by: National Institute for Health and Care Excellence Last published: 2019
EFNS guidelines on the molecular diagnosis of channelopathies, epilepsies,

migraine, stroke, and dementias
Published by: European Federation of Neurological Societies Last published: 2010
North America
2018 guidelines for the early management of patients with acute ischemic
GUIDELINES
stroke
Published by: American Heart Association; American Stroke Last published: 2018
Association
ACR appropriateness criteria: cerebrovascular disease

Published by: American College of Radiology Last published: 2016
Summary of evidence-based guideline update: prevention of stroke in

nonvalvular atrial fibrillation
Published by: American Academy of Neurology Last published: 2014
ACR appropriateness criteria: focal neurologic deficit

Published by: American College of Radiology Last published: 2012
45
Treatment guidelines
Europe
Stroke and transient ischaemic at tack in over 16s: diagnosis and initial
management
European Stroke Organisation (ESO) guidelines for prophylaxis for venous

thromboembolism in immobile patients with acute ischaemic stroke
Published by: European Stroke Organisation Last published: 2016
European Stroke Organisation (ESO) guidelines for the management of

temperature in patients with acute ischemic stroke
GUIDELINES
Alteplase for treating acute ischaemic stroke

Guidelines for management of ischaemic stroke and transient ischaemic

at tack
North America
2018 guidelines for the early management of patients with acute ischemic
stroke
Association
Acute stroke management: prehospital, emergency department, and acute

inpatient stroke care
Published by: Acute Stroke Management Best Practice Writing Group; Last published: 2018
Canadian Stroke Best Practices and Quality Advisory Committees;
Canadian Stroke Consortium; Canadian Association of Emergency
Physicians
Guidelines for adult stroke rehabilitation and recovery

GUIDELINES
Association
Summary of evidence-based guideline update: prevention of stroke in

nonvalvular atrial fibrillation
Published by: American Academy of Neurology Last published: 2014
Guidelines for the prevention of stroke in patients with stroke and transient
ischemic at tack
Association
Guidelines for the primary prevention of stroke

Published by: American Heart Association Last published: 2014
Antithrombotic and thrombolytic therapy for ischemic stroke: antithrombotic

therapy and prevention of thrombosis, 9th ed
Published by: American College of Chest Physicians Last published: 2012
Diagnosis and management of cerebral venous thrombosis

Published by: American Heart Association Last published: 2011
Stroke Treatment Academic Industry Roundtable (STAIR) recommendations

for maximizing the use of intravenous thrombolytics and expanding
treatment options with intra-arterial and neuroprotective therapies
Published by: Stroke Treatment Academic Industry Roundtable Last published: 2011
Updated Society for Vascular Surgery guidelines for management of

extracranial carotid disease
Published by: Society for Vascular Surgery Last published: 2011
47
North America
Anticoagulants and antiplatelet agents in acute ischemic stroke

Published by: American Academy of Neurology; American Heart Last published: 2002
Association
Africa
The South African guideline for the management of ischemic stroke and
transient ischemic at tack: recommendations for a resource-constrained
health care set ting
Published by: South African Stroke Society Last published: 2011
Oceania
GUIDELINES
Clinical guidelines for stroke management 2017

Published by: National Stroke Foundation (Australia) Last published: 2017
Ischaemic stroke Online resources
Online resources
1. Stroke Association: life after stroke (external link)
ONLINE RESOURCES
49
Ischaemic stroke Evidence scores
Evidence scores
1. Clinical outcomes: there is good-quality evidence that r-tPA administered between 3 and 4.5 hours
after the onset of symptoms significantly improved clinical outcomes in patients with acute ischaemic
stroke compared with placebo.[63]
Evidence level A: Systematic reviews (SRs) or randomized controlled trials (RCTs) of >200
participants.
EVIDENCE SCORES
Ischaemic stroke References
Key articles
• Kannel WB, Wolf PA, Verter J, et al. Epidemiologic assessment of the role of blood pressure in stroke:
REFERENCES
the Framingham study. JAMA. 1970 Oct 12;214(2):301-10. Abstract
• Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 guidelines for the early management of patients
with acute ischemic stroke: a guideline for healthcare professionals from the American Heart
Association/American Stroke Association. Stroke. 2018 Mar;49(3):e46-110. Full text Abstract
• National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen
activator for acute ischemic stroke. N Engl J Med. 1995 Dec 14;333(24):1581-7. Full text Abstract
• Sandercock PAG, Collins R, Counsell C, et al. The International Stroke Trial (IST): a randomised trial
of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke:
International Stroke Trial Collaborative Group. Lancet. 1997 May 31;349(9065):1569-81. Abstract
• Lansberg MG, O'Donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy for ischemic
stroke. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest
Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(2 suppl):e601-36S. Full
text Abstract
• Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke: the
PROACT II study: a randomized controlled trial. JAMA. 1999 Dec 1;282(21):2003-11. Full text
Abstract
• Vahedi K, Hofmeijer J, Juettler E, et al. Early decompressive surgery in malignant infarction of the
middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol. 2007
Mar;6(3):215-22. Abstract
References
1. Amarenco P, Lavallée PC, Labreuche J, et al. One-year risk of stroke after transient ischemic attack or
minor stroke. N Engl J Med. 2016 Apr 21;374(16):1533-42. Full text Abstract
2. Easton JD, Saver JL, Albers GW, et al. Definition and evaluation of transient ischemic attack: a
scientific statement for healthcare professionals from the American Heart Association/American
Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council
on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the
Interdisciplinary Council on Peripheral Vascular Disease. Stroke. 2009 Jun;40(6):2276-93. Full text
Abstract
3. Adams HP Jr, Bendixen BH, Kappelle LJ, et al; TOAST Investigators. Classification of subtype of acute
ischemic stroke: definitions for use in a multicenter clinical trial (TOAST - Trial of Org 10172 in Acute
Stroke Treatment). Stroke. 1993 Jan;24(1):35-41. Full text Abstract
51
4. Ay H, Benner T, Arsava EM, et al. A computerized algorithm for etiologic classification of ischemic
stroke: the causative classification of stroke system. Stroke. 2007 Nov;38(11):2979-84. Full text
Abstract
REFERENCES
5. Bamford J, Sandercock P, Dennis M, et al. Classification and natural history of clinically identifiable
subtypes of cerebral infarction. Lancet. 1991 Jun 22;337(8756):1521-6. Abstract
6. Wolfe C. The burden of stroke. In: Wolfe C, Rudd T, Beech R, eds. Stroke services and research.
London, UK: The Stroke Association; 1996.
7. Statistics Canada. The 10 leading causes of death, 2013. Mar 2017 [internet publication]. Full text
8. NHS National Services Scotland: Information Services Division. Scottish stroke statistics: year ending
31 March 2017. Jan 2018 [internet publication]. Full text
9. Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics - 2018 update: a
report from the American Heart Association. Circulation. 2018 Mar 20;137(12):e67-492. Full text
Abstract
10. Sacco RL. Risk factors, outcomes, and stroke subtypes for ischemic stroke. Neurology. 1997 Nov;49(5
suppl 4):S39-44. Abstract
11. Flossmann E, Schulz UG, Rothwell PM. Systematic review of methods and results of studies of the
genetic epidemiology of ischemic stroke. Stroke. 2004 Jan;35(1):212-27. Full text Abstract
12. Rosand J, Bayley N, Rost N, et al. Many hypotheses but no replication for the association between
PDE4D and stroke. Nat Genet. 2006 Oct;38(10):1091-2. Abstract
13. Kannel WB, Wolf PA, Verter J, et al. Epidemiologic assessment of the role of blood pressure in stroke:
the Framingham study. JAMA. 1970 Oct 12;214(2):301-10. Abstract
14. Wolf PA, D'Agostino RB, Kannel WB, et al. Cigarette smoking as a risk factor for stroke: the
Framingham study. JAMA. 1988 Feb 19;259(7):1025-9. Abstract
15. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. JAMA. 1979
May 11;241(19):2035-8. Abstract
16. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the
Framingham study. Stroke. 1991 Aug;22(8):983-8. Abstract
17. Goldstein LB, Adams R, Becker K, et al. Primary prevention of ischemic stroke: a statement for
healthcare professionals from the Stroke Council of the American Heart Association. Stroke. 2001
Jan;32(1):280-99. Full text Abstract
18. Chambers BR, Norris JW. Outcome in patients with asymptomatic neck bruits. N Engl J Med. 1986
Oct 2;315(14):860-5. Abstract
19. Barnett HJ, Taylor DW, Haynes RB, et al; North American Symptomatic Carotid Endarterectomy Trial
Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade
carotid stenosis. N Engl J Med. 1991 Aug 15;325(7):445-53. Full text Abstract
REFERENCES
20. Barnett HJ, Taylor DW, Eliasziw M, et al; North American Symptomatic Carotid Endarterectomy Trial
Collaborators. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe
stenosis. N Engl J Med. 1998 Nov 12;339(20):1415-25. Full text Abstract
21. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle
cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998 Jul
2;339(1):5-11. Full text Abstract
22. Iso H, Jacobs DR Jr, Wentworth D, et al. Serum cholesterol levels and six-year mortality from stroke
in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med. 1989 Apr
6;320(14):904-10. Abstract
23. Amarenco P, Labreuche J, Touboul PJ. High-density lipoprotein-cholesterol and risk of stroke and
carotid atherosclerosis: a systematic review. Atherosclerosis. 2008 Feb;196(2):489-96. Abstract
24. Broderick J, Brott T, Kothari R, et al. The Greater Cincinnati/Northern Kentucky Stroke Study:
preliminary first-ever and total incidence rates of stroke among blacks. Stroke. 1998 Feb;29(2):415-21.
Full text Abstract
25. Bazzano LA, Serdula MK, Liu S. Dietary intake of fruits and vegetables and risk of cardiovascular
disease. Curr Atheroscler Rep. 2003 Nov;5(6):492-9. Abstract
26. He J, Ogden LG, Vupputuri S, et al. Dietary sodium intake and subsequent risk of cardiovascular
disease in overweight adults. JAMA. 1999 Dec 1;282(21):2027-34. Full text Abstract
27. Khaw KT, Barrett-Connor E. Dietary potassium and stroke-associated mortality: a 12-year prospective
population study. N Engl J Med. 1987 Jan 29;316(5):235-40. Abstract
28. Sacco RL, Gan R, Boden-Albala B, et al. Leisure-time physical activity and ischemic stroke risk: the
Northern Manhattan stroke study. Stroke. 1998 Feb;29(2):380-7. Full text Abstract
29. Kurth T, Gaziano JM, Rexrode KM, et al. Prospective study of body mass index and risk of stroke in
apparently healthy women. Circulation. 2005 Apr 19;111(15):1992-8. Full text Abstract
30. Kurth T, Gaziano JM, Berger K, et al. Body mass index and the risk of stroke in men. Arch Intern Med.
2002 Dec 9-23;162(22):2557-62. Full text Abstract
31. Reynolds K, Lewis B, Nolen JD, et al. Alcohol consumption and risk of stroke: a meta-analysis. JAMA.
2003 Feb 5;289(5):579-88. Abstract
32. Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: a meta-
analysis. JAMA. 2000 Jul 5;284(1):72-8. Abstract
33. Hendrix SL, Wassertheil-Smoller S, Johnson KC, et al. Effects of conjugated equine estrogen on
stroke in the Women's Health Initiative. Circulation. 2006 May 23;113(20):2425-34. Full text Abstract
53
34. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy
postmenopausal women: principal results from the Women's Health Initiative randomized controlled
trial. JAMA. 2002 Jul 17;288(3):321-33. Full text Abstract
REFERENCES
35. Kurth T, Slomke MA, Kase CS, et al. Migraine, headache, and the risk of stroke in women: a
prospective study. Neurology. 2005 Mar 22;64(6):1020-6. Abstract
36. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke
to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke
Prevention (VISP) randomized controlled trial. JAMA. 2004 Feb 4;291(5):565-75. Full text Abstract
37. Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular
disease. N Engl J Med. 2006 Apr 13;354(15):1567-77. Full text Abstract
38. Bønaa KH, Njølstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute
myocardial infarction. N Engl J Med. 2006 Apr 13;354(15):1578-88. Full text Abstract
39. Kuo HK, Yen CJ, Chang CH, et al. Relation of C-reactive protein to stroke, cognitive disorders, and
depression in the general population: systematic review and meta-analysis. Lancet Neurol. 2005
Jun;4(6):371-80. Abstract
40. Di Tullio MR, Russo C, Jin Z, et al. Aortic arch plaques and risk of recurrent stroke and death.
Circulation. 2009 May 5;119(17):2376-82. Full text Abstract
41. Thompson AM, Hu T, Eshelbrenner CL, et al. Antihypertensive treatment and secondary prevention
of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA. 2011
Mar 2;305(9):913-22. Full text Abstract
42. Talbert RL. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or
angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention. J
Am Pharm Assoc (2003). 2010 Sep-Oct;50(5):e116-25. Abstract
43. Meschia JF, Bushnell C, Boden-Albala B, et al. Guidelines for the primary prevention of stroke:
a guideline for healthcare professionals from the American Heart Association/American Stroke
Association. Stroke. 2014 Dec;45(12):3754-832. Full text Abstract
44. Aguilar MI, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet therapy for preventing stroke
in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks.
Cochrane Database Syst Rev. 2007 Jul 18;(3):CD006186. Full text Abstract
45. Culebras A, Messé SR, Chaturvedi S, et al. Summary of evidence-based guideline update: prevention
of stroke in nonvalvular atrial fibrillation: report of the Guideline Development Subcommittee of the
American Academy of Neurology. Neurology. 2014 Feb 25;82(8):716-24. Full text Abstract
46. Alberts MJ, Latchaw RE, Jagoda A, et al. Revised and updated recommendations for the
establishment of primary stroke centers: a summary statement from the brain attack coalition. Stroke.
2011 Sep;42(9):2651-65. Full text Abstract
47. Johnston SC, Nguyen-Huynh MN, Schwarz ME, et al. National Stroke Association guidelines for the
management of transient ischemic attacks. Ann Neurol. 2006 Sep;60(3):301-13. Full text Abstract
REFERENCES
48. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines
for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis.
49. Sanna T, Diener HC, Passman RS, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J
Med. 2014 Jun 26;370(26):2478-86. Full text Abstract
50. Gladstone DJ, Spring M, Dorian P, et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J
Med. 2014 Jun 26;370(26):2467-77. Full text Abstract
51. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 guidelines for the early management of patients
with acute ischemic stroke: a guideline for healthcare professionals from the American Heart
Association/American Stroke Association. Stroke. 2018 Mar;49(3):e46-110. Full text Abstract
52. Kane I, Sandercock P, Wardlaw J. Magnetic resonance perfusion diffusion mismatch and thrombolysis
in acute ischaemic stroke: a systematic review of the evidence to date. J Neurol Neurosurg Psychiatry.
2007 May;78(5):485-91. Full text Abstract
53. Giles MF, Rothwell PM. Risk of stroke early after transient ischaemic attack: a systematic review and
meta-analysis. Lancet Neurol. 2007 Dec;6(12):1063-72. Abstract
54. Higgins P, MacFarlane PW, Dawson J, et al. Noninvasive cardiac event monitoring to detect atrial
fibrillation after ischemic stroke: a randomized, controlled trial. Stroke. 2013 Sep;44(9):2525-31. Full
text Abstract
55. Kucinski T. Unenhanced CT and acute stroke physiology. Neuroimaging Clin N Am. 2005
May;15(2):397-407. Abstract
56. Caplan L. Caplan's stroke: a clinical approach. 4th ed. Philadelphia, PA: Saunders; 2009.
57. Chalela JA, Kidwell CS, Nentwich LM, et al. Magnetic resonance imaging and computed tomography
in emergency assessment of patients with suspected acute stroke: a prospective comparison. Lancet.
2007 Jan 27;369(9558):293-8. Full text Abstract
58. Baird TA, Parsons MW, Phanh T, et al. Persistent poststroke hyperglycemia is independently
associated with infarct expansion and worse clinical outcome. Stroke. 2003 Sep;34(9):2208-14. Full
text Abstract
59. Kase CS, Furlan AJ, Wechsler LR, et al. Cerebral hemorrhage after intra-arterial thrombolysis for
ischemic stroke: the PROACT II trial. Neurology. 2001 Nov 13;57(9):1603-10. Abstract
60. Demchuk AM, Morgenstern LB, Krieger DW, et al. Serum glucose level and diabetes predict tissue
plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke. 1999
Jan;30(1):34-9. Full text Abstract
55
61. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with
stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart
Association/American Stroke Association. Stroke. 2014 Jul;45(7):2160-236. Full text Abstract
REFERENCES
62. Carpenter CR, Keim SM, Milne WK, et al. Thrombolytic therapy for acute ischemic stroke beyond three
hours. J Emerg Med. 2011 Jan;40(1):82-92. Full text Abstract
63. Hacke W, Kaste M, Bluhmki E, et al; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours
after acute ischemic stroke. N Engl J Med. 2008 Sep 25;359(13):1317-29. Full text Abstract
64. Whiteley WN, Emberson J, Lees KR, et al. Risk of intracerebral haemorrhage with alteplase after
acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis. Lancet
Neurol. 2016 Aug;15(9):925-33. Abstract
65. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen
activator for acute ischemic stroke. N Engl J Med. 1995 Dec 14;333(24):1581-7. Full text Abstract
66. Albers GW, Amarenco P, Easton JD, et al. Antithrombotic and thrombolytic therapy for ischemic stroke:
the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep;126(3
suppl):483-512S. Abstract
67. Bhatnagar P, Sinha D, Parker RA, et al. Intravenous thrombolysis in acute ischaemic stroke: a
systematic review and meta-analysis to aid decision making in patients over 80 years of age. J Neurol
Neurosurg Psychiatry. 2011 Jul;82(7):712-7. Full text Abstract
68. Zinkstok SM, Roos YB; ARTIS investigators. Early administration of aspirin in patients treated
with alteplase for acute ischaemic stroke: a randomised controlled trial. Lancet. 2012 Aug
25;380(9843):731-7. Abstract
69. Sandercock PAG, Collins R, Counsell C, et al. The International Stroke Trial (IST): a randomised trial
of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke:
International Stroke Trial Collaborative Group. Lancet. 1997 May 31;349(9065):1569-81. Abstract
70. CAST Collaborative Group. Randomised placebo-controlled trial of early aspirin use in 20,000 patients
with acute ischaemic stroke: CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet. 1997
Jun 7;349(9066):1641-9. Abstract
71. Lansberg MG, O'Donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy for ischemic
stroke. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest
Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(2 suppl):e601-36S. Full
text Abstract
72. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke: the
PROACT II study: a randomized controlled trial. JAMA. 1999 Dec 1;282(21):2003-11. Full text
Abstract
73. Sandercock PA, Counsell C, Kane EJ. Anticoagulants for acute ischaemic stroke. Cochrane Database
Syst Rev. 2015 Mar 12;(3):CD000024. Full text Abstract
74. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation
developed in collaboration with EACTS. Eur Heart J. 2016 Oct 7;37(38):2893-962. Full text Abstract
REFERENCES
75. Chu DK, Kim LH, Young PJ, et al. Mortality and morbidity in acutely ill adults treated with liberal
versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis. Lancet. 2018 Apr
28;391(10131):1693-705. Abstract
76. Siemieniuk RAC, Chu DK, Kim LH, et al. Oxygen therapy for acutely ill medical patients: a clinical
practice guideline. BMJ. 2018 Oct 24;363:k4169. Full text Abstract
77. Rønning OM, Guldvog B. Should stroke victims routinely receive supplemental oxygen? A quasi-
randomized controlled trial. Stroke. 1999 Oct;30(10):2033-7. Full text Abstract
78. Perkins GD, Olasveengen TM, Maconochie I, et al. European Resuscitation Council guidelines for
resuscitation: 2017 update. Resuscitation. 2018 Feb;123:43-50. Abstract
79. Colquhoun MC, Handley AJ, Evans TR, eds. ABC of resuscitation. 5th ed. Wiley-Blackwell; 2004.
80. Soar J, Nolan JP, Böttiger BW, et al. European Resuscitation Council guidelines for resuscitation 2015:
Section 3. Adult advanced life support. Resuscitation. 2015;95:100-147. Abstract
81. Ahmed N, Näsman P, Wahlgren NG. Effect of intravenous nimodipine on blood pressure and outcome
after acute stroke. Stroke. 2000 Jun;31(6):1250-5. Full text Abstract
82. Bruno A, Kent TA, Coull BM, et al. Treatment of hyperglycemia in ischemic stroke (THIS): a
randomized pilot trial. Stroke. 2008 Feb;39(2):384-9. Abstract
83. Walters MR, Weir CJ, Lees KR. A randomised, controlled pilot study to investigate the potential benefit
of intervention with insulin in hyperglycaemic acute ischaemic stroke patients. Cerebrovasc Dis.
2006;22(2-3):116-22. Abstract
84. Gray CS, Hildreth AJ, Sandercock PA, et al. Glucose-potassium-insulin infusions in the management
of post-stroke hyperglycaemia: the UK Glucose Insulin in Stroke Trial (GIST-UK). Lancet Neurol. 2007
May;6(5):397-406. Abstract
85. Reith J, Jorgensen HS, Pedersen PM, et al. Body temperature in acute stroke: relation to stroke
severity, infarct size, mortality, and outcome. Lancet. 1996 Feb 17;347(8999):422-5. Abstract
86. Krieger DW, Yenari MA. Therapeutic hypothermia for acute ischemic stroke: what do laboratory studies
teach us? Stroke. 2004 Jun;35(6):1482-9. Full text Abstract
87. Den Hertog HM, van der Worp HB, Tseng MC, et al. Cooling therapy for acute stroke. Cochrane
Database Syst Rev. 2009 Jan 21;(1):CD001247. Full text Abstract
88. Ntaios G, Dziedzic T, Michel P, et al. European Stroke Organisation (ESO) guidelines for
the management of temperature in patients with acute ischemic stroke. Int J Stroke. 2015
Aug;10(6):941-9. Full text Abstract
57
89. Stroke Unit Trialists' Collaboration. Organised inpatient (stroke unit) care for stroke. Cochrane
Database Syst Rev. 2013 Sep 11;(9):CD000197. Full text Abstract
REFERENCES
90. Martino R, Foley N, Bhogal S, et al. Dysphagia after stroke: incidence, diagnosis, and pulmonary
complications. Stroke. 2005 Dec;36(12):2756-63. Full text Abstract
91. Mann G, Hankey GJ, Cameron D. Swallowing function after stroke: prognosis and prognostic factors at
6 months. Stroke. 1999 Apr;30(4):744-8. Full text Abstract
92. Wijdicks EF, Scott JP. Pulmonary embolism associated with acute stroke. Mayo Clin Proc. 1997
Apr;72(4):297-300. Abstract
93. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College
of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008 Jun;133(6
94. Lacut K, Bressollette L, Le Gal G, et al. Prevention of venous thrombosis in patients with acute
intracerebral hemorrhage. Neurology. 2005 Sep 27;65(6):865-9. Abstract
95. European Stroke Organisation. European Stroke Organisation (ESO) guidelines for prophylaxis
for venous thromboembolism in immobile patients with acute ischaemic stroke. Mar 2016 [internet
publication]. Full text
96. Bath PM, Krishnan K, Appleton JP. Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase
inhibitors for acute stroke. Cochrane Database Syst Rev. 2017 Apr 21;(4):CD000398. Full text
Abstract
97. Ziganshina LE, Abakumova T, Vernay L. Cerebrolysin for acute ischaemic stroke. Cochrane Database
Syst Rev. 2017 Apr 21;(4):CD007026. Full text Abstract
98. Rothwell PM, Algra A, Chen Z, et al. Effects of aspirin on risk and severity of early recurrent stroke
after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials.
Lancet. 2016 Jul 23;388(10042):365-75. Full text Abstract
99. Badhiwala JH, Nassiri F, Alhazzani W, et al. Endovascular thrombectomy for acute ischemic stroke: a
meta-analysis. JAMA. 2015 Nov 3;314(17):1832-43. Full text Abstract
100. Goyal M, Menon BK, van Zwam WH, et al. Endovascular thrombectomy after large-vessel ischaemic
stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016 Apr
23;387(10029):1723-31. Abstract
101. Campbell BC, Hill MD, Rubiera M, et al. Safety and efficacy of solitaire stent thrombectomy: individual
patient data meta-analysis of randomized trials. Stroke. 2016 Mar;47(3):798-806. Full text Abstract
102. Berkhemer OA, Fransen PS, Beumer D, et al. A randomized trial of intraarterial treatment for acute
ischemic stroke. N Engl J Med. 2015 Jan 1;372(1):11-20. Full text Abstract
103. Campbell BC, Mitchell PJ, Kleinig TJ, et al; EXTEND-IA Investigators. Endovascular therapy for
ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015 Mar 12;372(11):1009-18. Full
text Abstract
REFERENCES
104. Goyal M, Demchuk AM, Menon BK, et al; ESCAPE Trial Investigators. Randomized assessment of
rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015 Mar 12;372(11):1019-30. Full
text Abstract
105. Jovin TG, Chamorro A, Cobo E, et al. Thrombectomy within 8 hours after symptom onset in ischemic
stroke. N Engl J Med. 2015 Jun 11;372(24):2296-306. Full text Abstract
106. Saver JL, Goyal M, Bonafe A, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone
in stroke. N Engl J Med. 2015 Jun 11;372(24):2285-95. Full text Abstract
107. Toth C, Voll C. Validation of a weight-based nomogram for the use of intravenous heparin in transient
ischemic attack or stroke. Stroke. 2002 Mar;33(3):670-4. Full text Abstract
108. Cooray C, Mazya M, Bottai M, et al. External validation of the ASTRAL and DRAGON scores for
prediction of functional outcome in stroke. Stroke. 2016 Jun;47(6):1493-9. Full text Abstract
109. Ferrarello F, Baccini M, Rinaldi LA, et al. Efficacy of physiotherapy interventions late after stroke: a
meta-analysis. J Neurol Neurosurg Psychiatry. 2011 Feb;82(2):136-43. Abstract
110. Saver JL. Number needed to treat estimates incorporating effects over the entire range of clinical
outcomes: novel derivation method and application to thrombolytic therapy for acute stroke. Arch
Neurol. 2004 Jul;61(7):1066-70. Full text Abstract
111. Starkstein SE, Mizrahi R, Power BD. Antidepressant therapy in post-stroke depression. Expert Opin
Pharmacother. 2008 Jun;9(8):1291-8. Abstract
112. Jensen MB, St Louis EK. Management of acute cerebellar stroke. Arch Neurol. 2005 Apr;62(4):537-44.
Full text Abstract
113. Vahedi K, Hofmeijer J, Juettler E, et al. Early decompressive surgery in malignant infarction of the
middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol. 2007
Mar;6(3):215-22. Abstract
114. Alawneh JA, Hutchinson PA, Warburton E. Stroke management: decompressive hemicraniectomy.
Systematic review 0201. BMJ Clin Evid. 2015;2015:0201. Full text
115. Winstein CJ, Stein J, Arena R, et al. Guidelines for adult stroke rehabilitation and recovery: a guideline
for healthcare professionals from the American Heart Association/American Stroke Association.
Stroke. 2016 Jun;47(6):e98-169. Full text Abstract
116. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial
fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994 Jul
11;154(13):1449-57. Abstract
59
117. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College
of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008 Jun;133(6
REFERENCES
118. Lane DA, Lip GY. Use of the CHA(2)DS(2)-VASc and HAS-BLED scores to aid decision making for
thromboprophylaxis in nonvalvular atrial fibrillation. Circulation. 2012 Aug 14;126(7):860-5. Full text
Abstract
119. Roldán V, Cancio S, Gálvez J, et al. The SAMe-TT2R2 score predicts poor anticoagulation control in
AF patients: a prospective 'real-world' inception cohort study. Am J Med. 2015 Nov;128(11):1237-43.
Abstract
120. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet

therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002 Jan
121. Halkes PH, van Gijn J, Kappelle LJ, et al. Aspirin plus dipyridamole versus aspirin alone after
cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. 2006 May
20;367(9523):1665-73. Abstract
122. Greenhalgh J, Bagust A, Boland A, et al. Clopidogrel and modified-release dipyridamole for the
prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review
and economic analysis. Health Technol Assess. 2011 Sep;15(31):1-178. Abstract
123. Kamal AK, Naqvi I, Husain MR, et al. Cilostazol versus aspirin for secondary prevention of vascular
events after stroke of arterial origin. Cochrane Database Syst Rev. 2011 Jan 19;(1):CD008076. Full
text Abstract
124. Li L, Geraghty OC, Mehta, Z, et al; Oxford Vascular Study. Age-specific risks, severity, time course,
and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based
cohort study. Lancet. 2017 Jul 29;390(10093):490-9. Full text Abstract
125. Orrapin S, Rerkasem K. Carotid endarterectomy for symptomatic carotid stenosis. Cochrane Database
Syst Rev. 2017 Jun 7;(6):CD001081. Full text Abstract
126. Bangalore S, Kumar S, Wetterslev J, et al. Carotid artery stenting vs carotid endarterectomy: meta-
analysis and diversity-adjusted trial sequential analysis of randomized trials. Arch Neurol. 2011
Feb;68(2):172-84. Full text Abstract
127. Ahmed N, Steiner T, Caso V, et al; ESO-KSU session participants. Recommendations from the
ESO-Karolinska Stroke Update Conference, Stockholm 13-15 November 2016. Eur Stroke J. 2017
Jun;2(2):95-102. Full text
Ischaemic stroke Images
Images
IMAGES
Figure 1: (A) T2-weighted MRI image showing hyperintense signal representing prolonged T2. Shows
abnormal T2 of 153.38 ms on the left, compared with the normal contralateral side (96 ms). Note that the
lesion is located on the ascending frontal gyrus. (B) Gradient echo images detect haemosiderin compounds
due to magnetic susceptibility of iron. In this case the result is negative
From the personal collection of Eric E. Smith; used with permission
61
IMAGES Ischaemic stroke Images
Figure 2: (A) Non-contrast T1-weighted MRI. (B) Post-contrast T1-weighted MRI showing minimal increase
in leptomeningeal vessels over the right frontal region. (C) Diffusion-weighted image (DWI) showing a
hyperintense area in the right frontal region. (D) Apparent diffusion coefficient (ADC) map shows hypointense
lesion, indicating restricted diffusion that correlates with high intensity on DWI and exponential diffusion. (E)
ADC value is 0.22 x 10¯³ mm²/second, corresponding to a hyperacute infarct
Ischaemic stroke Images
IMAGES
Figure 3: Non-contrast CT scan of brain showing sub-acute isolated left basal ganglion infarction with left
frontal horn mass effect
Courtesy of BMJ Case Reports 2009; doi:10.1136/bcr.10.2008.1139
63
IMAGES Ischaemic stroke Images
Figure 4: MRI arterial spin labelling image showing extensive hypoperfusion in the right cerebral hemisphere.
There is a clear mismatch between diffusion and perfusion
Ischaemic stroke Disclaimer
Disclaimer
This content is meant for medical professionals situated outside of the United States and Canada. The BMJ
Publishing Group Ltd ("BMJ Group") tries to ensure that the information provided is accurate and up-to-
date, but we do not warrant that it is nor do our licensors who supply certain content linked to or otherwise
accessible from our content. The BMJ Group does not advocate or endorse the use of any drug or therapy
contained within nor does it diagnose patients. Medical professionals should use their own professional
judgement in using this information and caring for their patients and the information herein should not be
considered a substitute for that.
This information is not intended to cover all possible diagnosis methods, treatments, follow up, drugs and
any contraindications or side effects. In addition such standards and practices in medicine change as new
data become available, and you should consult a variety of sources. We strongly recommend that users
independently verify specified diagnosis, treatments and follow up and ensure it is appropriate for your
patient within your region. In addition, with respect to prescription medication, you are advised to check the
product information sheet accompanying each drug to verify conditions of use and identify any changes
in dosage schedule or contraindications, particularly if the agent to be administered is new, infrequently
used, or has a narrow therapeutic range. You must always check that drugs referenced are licensed for the
specified use and at the specified doses in your region. This information is provided on an "as is" basis and
to the fullest extent permitted by law the BMJ Group and its licensors assume no responsibility for any aspect
of healthcare administered with the aid of this information or any other use of this information.
View our full Website Terms and Conditions.
Contact us
+ 44 (0) 207 111 1105

support@bmj.com
BMJ
BMA House
DISCLAIMER
Tavistock Square
London
WC1H 9JR
UK
65
Contributors:
// Authors:
George Ntaios, MD, MSc (ESO Stroke Medicine), PhD, FESO

Assistant Professor of Internal Medicine
Medical School, University of Thessaly, Secretary General, Hellenic Stroke Organization, Larissa University
Hospital, Larissa, Greece
DISCLOSURES: GN is on the advisory boards for, and has received honoraria, speaker fees, and research
support from: Amgen, Bayer, Boehringer-Ingelheim, BMS/Pfizer, Elpen, Galenica, Medtronic, Sanofi, and
Winmedica.
// Acknowledgements:
Dr George Ntaios would like to gratefully acknowledge Dr Alireza Minagar, the previous contributor to this
topic. AM declares that he has no competing interests.
// Peer Reviewers:
Julien Morier, MD
Neurology Registrar
Neurology Service, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
DISCLOSURES: JM declares that he has no competing interests.
Louis R. Caplan, MD
Lecturer in Neurology
Hospital Chief, Cerebrovascular/Stroke Division, Beth Israel Deaconess Medical Center, Division of
Cerebrovascular/Stroke, Boston, MA
DISCLOSURES: LRC declares that he has no competing interests.
Tony Rudd, MD
National Clinical Director
Stroke NHS England, Professor, Stroke Medicine, Kings College London, Chair, Intercollegiate Stroke
Working Party, Royal College of Physicians, London, UK
DISCLOSURES: TR declares that he has no competing interests.

BMJ Ischaemic Stroke

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

BMJ Ischaemic Stroke

Uploaded by

Copyright:

Available Formats

Ischaemic stroke

The right clinical information, right where it's needed

Last updated: Dec 06, 2018

◊ A leading cause of morbidity and mortality.

◊ Approximately 85% of strokes are ischaemic, caused by vascular occlusion.

◊ Care of patients in dedicated stroke units improves survival and function.

haemorrhagic stroke (caused by vascular rupture, resulting in intraparenchymal and/or subarachnoid

Pathophysiologically, ischaemic stroke can be broadly classified as:

• Haematological pathologies (e.g., prothrombotic hypercoagulable or hyperaggregable states) that

Large artery atherosclerosis

Stroke of indeterminate aetiology

Causative classification of stroke modified TOAST criteria[4]

• Large artery atherosclerosis

• Unknown - embolic stroke of undetermined source

Oxford Community Stroke Project classification system[5]

• Total anterior circulation infarction

Step-by-step diagnostic approach

[VIDEO: NIH Stroke Score ]

Prior medical information relevant to the acute management of stroke includes:

The most common anterior circulation stroke symptoms are:

• Limb and/or facial weakness

• Visual loss or double vision

• Neck or facial pain.

[VIDEO: ABCD2 Score to Predict Stroke Risk after TIA ]

Physical examination and neurological assessment

• Pure motor hemiparesis

[VIDEO: NIH Stroke Score ]

• CT angiography preferably (or MR angiography). Should be performed in all patients with

Optional vascular imaging

family history of stroke

history of ischaemic stroke

comorbid cardiac conditions

carotid artery stenosis

sickle cell disease

people with lower levels of education

poor diet and nutrition

illicit drug use

elevated C-reactive protein

aortic arch plaques

History & examination factors

impaired co-ordination (ataxia) (common)

Other diagnostic factors

sudden onset of symptoms (common)

altered sensation (common)

arrhythmias, murmurs, or pulmonary oedema (common)

nausea and/or vomiting (uncommon)

neck or facial pain (uncommon)

miosis, ptosis, and facial anhidrosis (hemilateral) (uncommon)

altered level of consciousness/coma (uncommon)

• May be implemented in the sub-acute phase after CT in some

Other tests to consider

conventional (invasive) angiography vascular occlusion or

Condition Differentiating signs / Differentiating tests

Transient ischaemic • Transient neurological • CT or MRI may be normal or

Hypertensive • The combination of • Cerebral oedema on CT or

Hypoglycaemia • There may be a history of • Low serum glucose at time

Complicated migraine • Repetitive history of similar • MRI shows no evidence of

Condition Differentiating signs / Differentiating tests

Seizure and postictal • Hx seizures; witnessed • Electroencephalogram

Conversion and • Neurological signs and • MRI shows no evidence of

Wernicke's • History of alcohol abuse. • Decreased blood thiamine

Brain tumour • Symptoms and signs more • CT head demonstrates

Step-by-step treatment approach

Contraindications to intravenous thrombolysis with r-tPA